US20140161800A1 - Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods - Google Patents

Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods Download PDF

Info

Publication number
US20140161800A1
US20140161800A1 US14/113,353 US201214113353A US2014161800A1 US 20140161800 A1 US20140161800 A1 US 20140161800A1 US 201214113353 A US201214113353 A US 201214113353A US 2014161800 A1 US2014161800 A1 US 2014161800A1
Authority
US
United States
Prior art keywords
psma
seq
amino acid
binding
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/113,353
Other languages
English (en)
Inventor
John W. Blankenship
Elaine Todd Sewell
Philip Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptevo Research and Development LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US14/113,353 priority Critical patent/US20140161800A1/en
Assigned to EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC reassignment EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BLANKENSHIP, JOHN W., TAN, PHILIP, SEWELL, Elaine Todd
Publication of US20140161800A1 publication Critical patent/US20140161800A1/en
Assigned to APTEVO RESEARCH AND DEVELOPMENT LLC reassignment APTEVO RESEARCH AND DEVELOPMENT LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
Priority to US15/585,921 priority patent/US9782478B1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Definitions

  • the present invention relates to mono-specific and multi-specific protein therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of disorders characterized by overexpression of PSMA, such as, for example, prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis, or benign prostatic hyperplasia (BPH).
  • PSMA prostate-specific membrane antigen
  • BPH benign prostatic hyperplasia
  • the multi-specific protein therapeutic binds both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.
  • Prostate-specific Membrane Antigen also known as glutamate carboxypeptidase II and N-acetylated alpha-linked acidic dipeptidase 1
  • PSMA Prostate-specific Membrane Antigen
  • FOLH1 farnesoid hydrolase 1
  • the protein acts as a glutamate carboxypeptidase on different alternative substrates, including the nutrient folate and the neuropeptide N-acetyl-I-aspartyl-I-glutamate and is expressed in a number of tissues such as the prostate, and to a lesser extent, the small intestine, central and peripheral nervous system and kidney.
  • the gene encoding PSMA is alternatively spliced to produce at least three variants.
  • a mutation in this gene may be associated with impaired intestinal absorption of dietary folates, resulting in low blood folate levels and consequent hyperhomocysteinemia.
  • Expression of this protein in the brain may be involved in a number of pathological conditions associated with glutamate excitotoxicity.
  • PSMA is a well-established, highly restricted prostate-cancer-related cell membrane antigen. In prostate cancer cells, PSMA is expressed 1000-fold higher than on normal prostate epithelium (Su et al., Cancer Res. 1995 44:1441-1443). Expression of PSMA increases with prostate cancer progression and is highest in metastatic disease, hormone refractory cases, and higher-grade lesions (Israeli et al., Cancer Res. 1994, 54:1807-1811; Wright et al., Urologic Oncology: Seminars and Original Investigations 1995 1:18-28; Wright et al., Urology 1996 48:326-332; Sweat et al., Urology 1998 52:637-640).
  • PSMA is abundantly expressed on the neovasculature of a variety of other solid tumors, including bladder, pancreas, melanoma, lung and kidney cancers, but not on normal neovasculature (Chang et al., Urology 2001 57:801-805; Divgi et al., Clin. Cancer Res. 1998 4:2729-3279).
  • PSMA has been shown to be an important target for immunological approaches such as vaccines or directed therapy with monoclonal antibodies.
  • PSMA secretory proteins
  • PSMA prostatic acid phosphatase
  • PSMA is an integral cell-surface membrane protein that is not secreted, which makes it an ideal target for antibody therapy.
  • PROSTASCINT® capromab pendetide
  • PROSTASCINT® is an 111 In-labelled anti-PSMA murine monoclonal antibody approved by the FDA for imaging and staging of newly diagnosed and recurrent prostate cancer patients (Hinkle et al., Cancer 1998, 83:739-747).
  • capromab binds to an intracellular epitope of PSMA, requiring internalization or exposure of the internal domain of PSMA, therefore preferentially binding apoptotic or necrosing cells (Troyer et al., Urologic Oncology: Seminars and Original Investigations 1995 1:29-37; Troyer et al., Prostate 1997 30:232-242). As a result, capromab may not be of therapeutic benefit (Liu et al., Cancer Res. 1997 57:3629-3634).
  • PSMA-specific internalizing antibodies may aid in the development of therapeutics to target the delivery of toxins, drugs, or radioisotopes to the interior of prostate cancer cells (Tagawa et al., Cancer 2010 116(S4):1075)
  • PSMA-specific antibodies utilizing native or engineered effector mechanisms e.g., antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated phagocytosis (ADCP), or re-directed T-cell cytotoxicity (RTCC)
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • ADCP antibody-dependent cell-mediated phagocytosis
  • RTCC re-directed T-cell cytotoxicity
  • the present disclosure provides a prostate-specific membrane antigen (PSMA)-binding polypeptide comprising, in order from amino-terminus to carboxyl-terminus, (a) a PSMA-binding domain that specifically binds human PSMA, (b) a hinge region, and (c) an immunoglobulin constant region.
  • PSMA-binding domains include binding domains that compete for binding to human PSMA with a single chain Fv (scFv) having the amino acid sequence set forth in SEQ ID NO:21.
  • scFv single chain Fv
  • the PSMA-binding polypeptide is capable of forming a dimer with a second, identical polypeptide chain through association between the respective immunoglobulin constant regions and/or hinge regions.
  • the PSMA-binding domain comprises (i) an immunoglobulin light chain variable region comprising CDRs LCDR1, LCDR2, and LCDR3, and/or (ii) an immunoglobulin heavy chain variable region comprising CDRs HCDR1, HCDR2, and HCDR3.
  • LCDR3 has the amino acid sequence set forth in SEQ ID NO:17 and/or HCDR3 has the amino acid sequence set forth in SEQ ID NO:11; in some such embodiments, LCDR1 and LCDR2 have the amino acid sequences as set forth in SEQ ID NO:15 and SEQ ID NO:16, respectively, and/or HCDR1 and HCDR2 have the amino acid sequences as set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively.
  • the light chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:5 or SEQ ID NO:23; and/or (ii) the heavy chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:25, or SEQ ID NO:27.
  • One or both of the light and heavy chain variable regions can be humanized.
  • the PSMA-binding domain is a single chain Fv (scFv) comprising the immunoglobulin light and heavy chain variable regions disclosed herein.
  • PSMA-binding scFvs include, for example, scFvs comprising an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:34, or SEQ ID NO:35.
  • the heavy chain variable region of the scFv is carboxyl-terminal to the light chain variable region (also referred to herein as a “VL-VH orientation”).
  • the scFv comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:30, or SEQ ID NO:31.
  • the hinge region is derived from an immunoglobulin hinge region, such as, for example, an immunoglobulin hinge region of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgD.
  • an immunoglobulin hinge region can be either a wild-type or an altered immunoglobulin hinge region.
  • the immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains, such as, for example, immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgD.
  • the immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains and the constant region does not comprise an immunoglobulin CH1 domain.
  • a PSMA-binding polypeptide disclosed herein includes at least one effector function selected from antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • the hinge region is derived from an immunoglobulin hinge region and the immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, or IgG4.
  • the immunoglobulin hinge region is derived from the hinge region of IgG1 and the immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains of IgG1.
  • a PSMA-binding polypeptide disclosed herein comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:70, or SEQ ID NO:72.
  • a PSMA-binding polypeptide disclosed herein further includes (d) a second hinge region carboxyl-terminal to the immunoglobulin constant region, and (e) a second binding domain carboxyl-terminal to the second hinge region.
  • second hinge regions include those derived from a stalk region of a type II C lectin or an immunoglobulin hinge region.
  • the second hinge region has an amino acid sequence as set forth in SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, or SEQ ID NO:66.
  • the present disclosure provides a prostate-specific membrane antigen (PSMA)-binding polypeptide that specifically binds human PSMA and comprises a first binding domain comprising (i) an immunoglobulin light chain variable region comprising CDRs LCDR1, LCDR2, and LCDR3, and (ii) an immunoglobulin heavy chain variable region comprising CDRs HCDR1, HCDR2, and HCDR3; wherein LCDR3 has the amino acid sequence set forth in SEQ ID NO:17 and/or HCDR3 has the amino acid sequence set forth in SEQ ID NO:11.
  • PSMA prostate-specific membrane antigen
  • LCDR1 and LCDR2 have the amino acid sequences as set forth in SEQ ID NO:15 and SEQ ID NO:16, respectively, and/or HCDR1 and HCDR2 have the amino acid sequences as set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively.
  • LCDR1, LCDR2, and LCDR3 have the amino acid sequences as set forth in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively; and HCDR1, HCDR2, and HCDR3 have the amino acid sequences as set forth in SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, respectively.
  • the light chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:5 or SEQ ID NO:23; and/or (ii) the heavy chain variable region comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:25, or SEQ ID NO:27.
  • the light chain variable region is encoded by a nucleic acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:22; and/or the heavy chain variable region is encoded by a nucleic acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:24, or SEQ ID NO:26.
  • the PSMA-binding polypeptide is capable of forming a dimer with a second, identical polypeptide chain.
  • the first binding domain is a single chain Fv (scFv) comprising the immunoglobulin light and heavy chain variable regions.
  • PSMA-binding scFvs include, for example, scFvs comprising an amino acid sequence that is at least 90%, at least 95% at least 99%, or 100% identical to the amino acid set forth in SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:34, or SEQ ID NO:35.
  • the heavy chain variable region of the scFv is carboxyl-terminal to the light chain variable region (a “VL-VH orientation”).
  • the scFv comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:30, or SEQ ID NO:31.
  • the PSMA-binding polypeptide further includes an immunoglobulin constant region.
  • the immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgD.
  • the PSMA-binding polypeptide further includes one or more hinge regions.
  • the hinge region can be derived, for instance, from a stalk region of a type II C lectin or from an immunoglobulin hinge region.
  • the PSMA binding polypeptide comprises, in order from amino to carboxyl-terminus, a first binding domain, a hinge region, and an immunoglobulin constant region.
  • a PSMA-binding polypeptide in this format can also be referred to as a PSMA-specific SMIP molecule.
  • General SMIP configurations are provided, for example, in US Patent Application Publication Nos. 2003/0133939, 2003/0118592, and 2005/0136049, which are incorporated herein in their entirety by reference.
  • the orientation of the polypeptide is reversed such that the polypeptide comprises, in order from amino to carboxyl-terminus, an immunoglobulin constant region, a hinge region and a first binding domain.
  • the polypeptide can also be referred to as a PSMA-specific PIMS molecule.
  • General PIMS configurations are provided, for example, in US Patent Application Publication No. 2009/0148447, which is incorporated herein in its entirety by reference.
  • a PSMA-binding polypeptide having an immunoglobulin constant region and, optionally, a hinge region as disclosed herein is capable of forming a dimer with a second, identical polypeptide chain through association between the respective immunoglobulin constant regions and/or hinge regions.
  • the PSMA-binding polypeptide includes a second binding domain, such as, e.g., a single-chain Fv (scFv).
  • a second binding domain such as, e.g., a single-chain Fv (scFv).
  • the PSMA-binding polypeptide comprises, in order from amino-terminus to carboxyl-terminus or in order from carboxyl-terminus to amino-terminus, (a) a first binding domain, (b) a first hinge region, (c) an immunoglobulin constant region, (d) a second hinge region, and (e) a second binding domain.
  • the present disclosure provides a PSMA-binding polypeptide as in other embodiments disclosed herein and comprising an additional binding domain, e.g., a second binding domain, wherein the second binding domain specifically binds a T cell.
  • the second binding domain specifically binds a T cell receptor (TCR) complex or a component thereof.
  • the second binding domain includes those that specifically bind CD3, e.g., CD3 ⁇ .
  • the second binding domain competes for binding to CD3 with the CRIS-7 or HuM291 monoclonal antibody.
  • the second binding domain comprises an immunoglobulin light chain variable region and an immunoglobulin heavy chain variable region derived from the CRIS-7 or HuM291 monoclonal antibody.
  • the light and heavy chain variable regions of the second binding domain are humanized variable regions comprising, respectively, the light and heavy chain CDRs of the CRIS-7 or HuM291 monoclonal antibody.
  • the light and heavy chain variable regions of the second binding domain are selected from (a) a light chain variable region comprising an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in residues 139-245 of SEQ ID NO:47 and a heavy chain variable region comprising an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in residues 1-121 of SEQ ID NO:47; and (b) a light chain variable region comprising an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in residues 634-740 of SEQ ID NO:78 and a heavy chain variable region comprising an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in residues 496-616 of SEQ ID NO:78.
  • the second binding domain is a single-chain Fv (scFv).
  • scFv single-chain Fv
  • the second binding domain is a scFv comprising an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to an amino acid sequence selected from (i) the amino acid sequence set forth in residues 1-245 of SEQ ID NO:47, and (ii) the amino acid sequence set forth in residues 496-742 of SEQ ID NO:78.
  • the PSMA-binding polypeptide comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:158, SEQ ID NO:160, SEQ ID NO:162, or SEQ ID NO:164.
  • the present disclosure provides a dimeric PSMA-binding protein comprising first and second polypeptide chains, wherein each of said polypeptide chains is a PSMA-binding polypeptide as in any of the embodiments disclosed herein.
  • the present disclosure provides a PSMA-binding polypeptide comprising, in order from amino-terminus to carboxyl-terminus, (a) a binding domain that specifically binds human PSMA, (b) a hinge region, (c) an immunoglobulin constant region, and (d) an immunoglobulin heterodimerization domain.
  • the heterodimerization domain can comprise, for example, an immunoglobulin CH1 domain or an immunoglobulin CL domain.
  • the PSMA-binding domain competes for binding to human PSMA with a single chain Fv (scFv) having the amino acid sequence set forth in SEQ ID NO:21.
  • the PSMA-binding domains include, e.g., the PSMA-binding domains disclosed above.
  • the hinge region is derived from an immunoglobulin hinge region, such as, for example, an immunoglobulin hinge region of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgD.
  • an immunoglobulin hinge region can be either a wild-type or an altered immunoglobulin hinge region.
  • the immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains, such as, for example, immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, or any combination thereof; an immunoglobulin CH3 domain of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, IgM or any combination thereof; or immunoglobulin CH3 and CH4 domains of IgE, IgM or a combination thereof.
  • immunoglobulin CH2 and CH3 domains such as, for example, immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, or any combination thereof; an immunoglobulin CH3 domain of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, IgM
  • a PSMA-binding polypeptide includes at least one effector function selected from antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • the hinge region is derived from an immunoglobulin hinge region and the immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, or IgG4.
  • the immunoglobulin hinge region is derived from the hinge region of IgG1 and the immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains of IgG1.
  • a PSMA-binding polypeptide comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100%% identical to the amino acid sequence set forth in SEQ ID NO:46, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, or SEQ ID NO:61.
  • the present disclosure provides a PSMA-binding protein comprising two, non-identical polypeptide chains that associate by way of heterodimerization domains (e.g., immunoglobulin heterodimerization domains) to form a heterodimer.
  • heterodimerization domains e.g., immunoglobulin heterodimerization domains
  • the heterodimeric PSMA binding protein comprises a first polypeptide chain comprising, in order from amino-terminus to carboxyl-terminus, (a) a first binding domain that specifically binds PSMA, (b) a first hinge region, (c) a first immunoglobulin constant region, and (d) a first immunoglobulin heterodimerization domain; and a second single chain polypeptide comprising, in order from amino-terminus to carboxyl-terminus, (a′) a second hinge region, (b′) a second immunoglobulin sub-region, and (c′) a second immunoglobulin heterodimerization domain that is different from the first immunoglobulin heterodimerization domain of the first polypeptide chain, wherein the first and second immunoglobulin heterodimerization domains associate with each other to form a heterodimer.
  • the PSMA-binding domain competes for binding to human PSMA with a single chain Fv (scFv) having the amino acid sequence set forth in SEQ ID NO:21.
  • the PSMA-binding domains include, e.g., the PSMA-binding domains disclosed above.
  • heterodimerization domains include domains comprising either an immunoglobulin CH1 domain or an immunoglobulin CL domain.
  • the first immunoglobulin heterodimerization domain comprises a first immunoglobulin CH1 domain and the second immunoglobulin heterodimerization domain comprises a first immunoglobulin CL domain.
  • the first immunoglobulin heterodimerization domain comprises a first immunoglobulin CL domain and the second immunoglobulin heterodimerization domain comprises a first immunoglobulin CH1 domain.
  • At least one of the first and second hinge regions is derived from an immunoglobulin hinge region, such as, for example, an immunoglobulin hinge region of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgD.
  • an immunoglobulin hinge region can be either a wild-type or an altered immunoglobulin hinge region.
  • At least one of the first and second immunoglobulin constant regions comprises immunoglobulin CH2 and CH3 domains, such as, for example, immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, or any combination thereof; an immunoglobulin CH3 domain of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, IgM or any combination thereof; or immunoglobulin CH3 and CH4 domains of IgE, IgM or a combination thereof.
  • immunoglobulin CH2 and CH3 domains such as, for example, immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, or any combination thereof; an immunoglobulin CH3 domain of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD,
  • one or both of the first and second polypeptide chains include at least one effector function selected from antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • each of the first and second hinge regions is derived from an immunoglobulin hinge region and each of the first and second immunoglobulin constant regions comprises immunoglobulin CH2 and CH3 domains of IgG1, IgG2, IgG3, or IgG4.
  • each of the first and second hinge regions is derived from the hinge region of IgG1 and each of the first and second immunoglobulin constant region comprises immunoglobulin CH2 and CH3 domains of IgG1.
  • the second polypeptide chain further includes a second binding domain.
  • the second polypeptide chain can further comprise a second binding domain amino-terminal to the second hinge region.
  • a heterodimeric PSMA-binding protein as disclosed herein can be monospecific (i.e., monospecific for PSMA).
  • the heterodimeric PSMA-binding protein is multispecific.
  • each polypeptide chain of the heterodimer can comprise different binding domains, e.g., the first polypeptide chain comprising the PSMA-binding domain and the second polypeptide chain comprising a second binding (e.g., amino-terminal to the second hinge region) that is specific for a second target antigen that is different from PSMA.
  • the second binding domain specifically binds a T-cell.
  • T-cell-binding domains include, e.g., the additional binding domains and second binding domains disclosed above.
  • the first polypeptide chain comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 46 and the second polypeptide chain comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 47;
  • the first polypeptide chain comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 58 and the second polypeptide chain comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 57;
  • the first polypeptide chain comprises an amino acid sequence that is at least 90%, at least 95%, at least 99%
  • the PSMA-binding protein exhibits increased serum half-life, reduced internalization by a cell expressing PSMA, and/or increased time of persistence on the surface of the cell expressing PSMA as compared to the murine monoclonal antibody 107-1A4.
  • the present disclosure provides an isolated nucleic acid encoding a PSMA-binding polypeptide.
  • the nucleic acid comprises the nucleotide sequence set forth in SEQ ID NO NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:53, SEQ ID: NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:157
  • the present disclosure provides an expression vector for expressing a PSMA-binding polypeptide or protein as disclosed herein in a recombinant host cell.
  • the expression vector comprises a nucleic acid segment encoding the PSMA-binding polypeptide, wherein the nucleic acid segment is operably linked to regulatory sequences suitable for expression of the nucleic acid segment in a host cell.
  • the nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:53, SEQ ID: NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:157, SEQ ID NO:159, SEQ ID NO:161, or SEQ ID NO:163.
  • the expression vector comprises first and second expression units, wherein the first and second expression units respectively comprise first and second nucleic acid segments encoding the first and second polypeptide chains of a heterodimeric PSMA-binding protein as in certain embodiments disclosed herein, and wherein the first and second nucleic acid segments are operably linked to regulatory sequences suitable for expression of the nucleic acid segments in a host cell.
  • the first nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:44 and the second nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:45;
  • the first nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:53 and the second nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:52;
  • the first nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:54 and the second nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:52;
  • the first nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:55 and the second nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:45; or
  • the first nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO:56 and the second nucleic acid segment comprises the nucleotide sequence set forth in SEQ
  • the present disclosure provides a recombinant host cell comprising an expression vector disclosed herein.
  • the present disclosure provides a method for producing a PSMA-binding polypeptide or protein.
  • the method is for producing a PSMA-binding polypeptide as disclosed herein.
  • the method generally includes culturing a recombinant host cell comprising an expression vector, wherein the expression vector comprises a nucleic acid segment that encodes the PSMA-binding polypeptide and is operably linked to regulatory sequences suitable for expression of the nucleic acid segment in the host cell, and wherein the culturing is under conditions whereby the nucleic acid segment is expressed, thereby producing the PSMA-binding polypeptide.
  • the nucleic acid segment comprises the nucleotide sequence set forth in SEQ ID NO NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:53, SEQ ID: NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:157, SEQ ID NO:159, SEQ ID NO:161, or SEQ ID NO:163.
  • the method comprises the nucleot
  • the method is for producing a dimeric PSMA-binding protein as disclosed herein.
  • the nucleic acid segment of the expression vector encodes the PSMA-binding polypeptide as disclosed herein, and the culturing is under conditions whereby the nucleic acid segment is expressed and the encoded PSMA-binding polypeptide is produced as a dimeric PSMA-binding protein.
  • the method can further include recovering the dimeric PSMA-binding protein.
  • the method is for producing a heterodimeric PSMA-binding protein disclosed herein.
  • the method generally includes culturing a recombinant host cell comprising first and second expression units, wherein the first and second expression units respectively comprise first and second nucleic acid segments encoding the first and second polypeptide chains of a heterodimeric PSMA-binding protein as set forth herein, wherein the first and second nucleic acid segments are operably linked to regulatory sequences suitable for expression of the nucleic acid segments in a host cell, and wherein the culturing is under conditions whereby the first and second nucleic acid segments are expressed and the encoded polypeptide chains are produced as the heterodimeric PSMA-binding protein.
  • the method further includes recovering the heterodimeric PSMA-binding protein.
  • the present disclosure provides a composition comprising any of the PSMA-binding polypeptides or proteins as set forth herein and a pharmaceutically acceptable carrier, diluent, or excipient.
  • the present disclosure provides a method for inducing antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) against a cell expressing PSMA.
  • a method for inducing ADCC or CDC against the cell expressing PSMA includes contacting the PSMA-expressing cell with a dimeric PSMA-binding protein comprising first and second polypeptide chains, wherein each of the polypeptide chains is a PSMA-binding polypeptide as disclosed herein, and wherein the contacting is under conditions whereby ADCC or CDC against the PSMA-expressing cell is induced.
  • a method for inducing ADCC or CDC against the PSMA-expressing cell includes contacting the cell with a heterodimeric PSMA-binding protein as in paragraph [0031], wherein the contacting is under conditions whereby ADCC or CDC against the PSMA-expressing cell is induced.
  • a method for inducing RTCC against the cell expressing PSMA includes contacting the PSMA-expressing cell with a dimeric PSMA-binding protein comprising first and second polypeptide chains, wherein each of said polypeptide chains is a PSMA-binding polypeptide disclosed herein, and wherein the contacting is under conditions whereby RTCC against the PSMA-expressing cell is induced.
  • a method for inducing RTCC against the PSMA-expressing cell includes contacting the cell with a heterodimeric PSMA-binding protein as disclosed herein, wherein the contacting is under conditions whereby RTCC against the PSMA-expressing cell is induced.
  • the present disclosure provides a method for treating a disorder in a subject, wherein the disorder is characterized by overexpression of PSMA.
  • the method includes administering to the subject a therapeutically effective amount of a dimeric PSMA-binding protein disclosed above.
  • the first and second polypeptide chains of the dimeric PSMA-binding protein is a PSMA-binding polypeptide, e.g., as disclosed above, and the dimeric PSMA-binding protein induces redirected T-cell cytotoxicity (RTCC) in the subject.
  • the method includes administering to the subject a therapeutically effective amount of a heterodimeric PSMA-binding protein, e.g., as disclosed above.
  • the heterodimeric PSMA-binding protein is a protein as disclosed above, and the heterodimeric PSMA-binding protein induces RTCC in the subject.
  • the disorder is a cancer such as, for example, prostate cancer (e.g., castrate-resistant prostate cancer), colorectal cancer, gastric cancer, clear cell renal carcinoma, bladder cancer, or lung cancer.
  • the disorder is a prostate disorder such as, e.g., prostate cancer or benign prostatic hyperplasia.
  • the disorder is an neovascular disorder.
  • the neovascular disorder to be treated can be, for example, a cancer characterized by solid tumor growth such as, e.g., clear cell renal carcinoma, colorectal cancer, bladder cancer, and lung cancer.
  • FIG. 1 is a graph illustrating the results of a binding study used to compare the parent 107-1A4 murine antibody (TSC045) with TSC085, TSC092 and TSC122 in PSMA(+) (LNCaP) and PSMA( ⁇ ) (DU-145) prostate cancer cell lines.
  • FIG. 2A is a graph illustrating the results of a binding study used to compare humanized TSC188 and TSC189 in PSMA(+) (C4-2) and PSMA( ⁇ ) (DU-145) prostate cancer cell lines.
  • FIG. 2B is a graph illustrating the results of a binding study used to compare binding of humanized SCORPION molecules TSC194 and TSC199 to that of parent humanized SMIP molecules TSC188 and TSC189 and chimeric Interceptor molecule TSC122 in PSMA(+) (C4-2) and PSMA( ⁇ ) (DU-145) prostate cancer cell lines.
  • FIG. 3 is a graph illustrating the results of internalization experiments comparing the parent 107-1A4 murine antibody to PSMA-binding proteins built on Interceptor and SMIP scaffolds.
  • FIG. 4 is a graph illustrating potent target-dependent cytotoxic activity over 24 hours observed with the chimeric TSC122 Interceptor molecule at decreasing concentrations (300, 100, 30, 10 and 0 pM) in the presence of T cells from human blood from two different donors (labeled as AG and VV).
  • FIG. 5 is a graph illustrating cytotoxicity activity of TSC200; TSC202, TSC204 alongside the parent chimeric Interceptor molecule TSC122.
  • FIG. 6 is a graph illustrating T-cell cytotoxicity mediated by humanized 107-1A4 SCORPION molecules (TSC194, TSC199, TSC212, TSC213) compared to the chimeric Interceptor molecule TSC122.
  • FIGS. 7A and 7B are graphs illustrating target-dependent proliferation of CD4+ T-cells ( FIG. 7A ) and CD8+ T-cells ( FIG. 7B ) induced by anti-PSMA bispecific molecules (TSC194, TSC199, TSC202 and TSC122) reacting with C4-2 cells.
  • TSC194, TSC199, TSC202 and TSC122 anti-PSMA bispecific molecules
  • FIGS. 8A-8C are graphs illustrating competitive binding studies of mAbs J591 and J415 versus 107-1A4 mAb and chimeric and humanized 107-1A4 SMIP molecules to PSMA on C4-2 cells.
  • FIG. 8A shows the results of a competitive binding assay to determine if the humanized J591 antibody (Hu591) competes with the binding of 107-1A4, J591 or J415 murine antibodies to PSMA on C4-2 cells
  • FIG. 8B shows the results of a competitive binding assay to determine if the three murine antibodies compete with the binding of the chimeric 107-1A4 SMIP molecule (TSC085) to PSMA on C4-2 cells
  • FIG. 8C shows the results of a competitive binding assay to determine if the three murine antibodies compete with the binding of the humanized 107-1A4 SMIP molecule (TSC189) to PSMA on C4-2 cells.
  • the invention provides PSMA-binding polypeptides and proteins that specifically bind prostate-specific membrane antigen (PSMA).
  • PSMA prostate-specific membrane antigen
  • Administration of a therapeutically effective amount of a PSMA-binding polypeptide or protein of the invention to a patient in need thereof is useful for treatment of certain disorders associated with the over-expression of PSMA, including certain cancers and prostate disorders.
  • the PSMA-binding polypeptide or protein simultaneously bind a target cell over-expressing PSMA and a T-cell, thereby “cross-linking” the target cell over-expressing PSMA and the T-cell.
  • the binding of both domains to their targets elicits potent target-dependent redirected T-cell cytotoxicity (RTCC) (e.g., induces target-dependent T-cell cytotoxicity, T-cell activation and T-cell proliferation).
  • RTCC potent target-dependent redirected T-cell cytotoxicity
  • any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
  • “about” means ⁇ 20% of the indicated range, value, or structure, unless otherwise indicated.
  • the terms “a” and “an” as used herein refer to “one or more” of the enumerated components unless otherwise indicated.
  • the use of the alternative should be understood to mean either one, both, or any combination thereof of the alternatives.
  • the terms “include” and “comprise” are used synonymously.
  • polypeptides comprising the various combinations of the components (e.g., domains or regions) and substituents described herein, are disclosed by the present application to the same extent as if each polypeptide was set forth individually. Thus, selection of particular components of individual polypeptides is within the scope of the present disclosure.
  • binding domain refers to the domain, region, portion, or site of a protein, polypeptide, oligopeptide, or peptide that possesses the ability to specifically recognize and bind to a target molecule, such as an antigen, ligand, receptor, substrate, or inhibitor (e.g., CD3, PSMA).
  • exemplary binding domains include single-chain antibody variable regions (e.g., domain antibodies, sFv, scFv, scFab), receptor ectodomains, and ligands (e.g., cytokines, chemokines).
  • the binding domain comprises or consists of an antigen binding site (e.g., comprising a variable heavy chain sequence and variable light chain sequence or three light chain complementary determining regions (CDRs) and three heavy chain CDRs from an antibody placed into alternative framework regions (FRs) (e.g., human FRs optionally comprising one or more amino acid substitutions).
  • an antigen binding site e.g., comprising a variable heavy chain sequence and variable light chain sequence or three light chain complementary determining regions (CDRs) and three heavy chain CDRs from an antibody placed into alternative framework regions (FRs) (e.g., human FRs optionally comprising one or more amino acid substitutions).
  • FRs alternative framework regions
  • a PSMA-binding polypeptide can have a “first binding domain” and, optionally, a “second binding domain.”
  • the “first binding domain” is a PSMA-binding domain and, depending on the particular polypeptide format (e.g., SMIP or PIMS), can be located at either the amino- or carboxyl-terminus.
  • the second binding domain is a T cell binding domain such as a scFv derived from a mouse monoclonal antibody (e.g., CRIS-7) that binds to a T cell surface antigen (e.g., CD3).
  • the second binding domain is a second PSMA-binding domain.
  • the second binding domain is a binding domain other than a PSMA-binding domain or a T cell binding domain.
  • a binding domain “specifically binds” a target if it binds the target with an affinity or K a (i.e., an equilibrium association constant of a particular binding interaction with units of 1/M) equal to or greater than 10 5 M ⁇ 1 , while not significantly binding other components present in a test sample. Binding domains can be classified as “high affinity” binding domains and “low affinity” binding domains.
  • “High affinity” binding domains refer to those binding domains with a K a of at least 10 7 M ⁇ 1 , at least 10 8 M ⁇ 1 , at least 10 9 M ⁇ 1 , at least 10 10 M ⁇ 1 , at least 10 11 M ⁇ 1 , at least 10 12 M ⁇ 1 , or at least 10 13 M ⁇ 1
  • “Low affinity” binding domains refer to those binding domains with a K a of up to 10 7 M ⁇ 1 , up to 10 6 M ⁇ 1 , up to 10 5 M ⁇ 1 .
  • affinity can be defined as an equilibrium dissociation constant (K d ) of a particular binding interaction with units of M (e.g., 10 ⁇ 5 M to 10 ⁇ 13 M).
  • binding domain polypeptides and single chain polypeptides can be readily determined using conventional techniques (see, e.g., Scatchard et al. (1949) Ann. N.Y. Acad. Sci. 51:660; and U.S. Pat. Nos. 5,283,173, 5,468,614, or the equivalent).
  • CD3 is known in the art as a multi-protein complex of six chains (see, e.g., Abbas and Lichtman, 2003; Janeway et al., p. 172 and 178, 1999), which are subunits of the T cell receptor complex.
  • the CD3 subunits of the T cell receptor complex are a CD3 ⁇ chain, a CD3 ⁇ chain, two CD3 ⁇ chains, and a homodimer of CD3 ⁇ chains.
  • the CD3 ⁇ , CD3 ⁇ , and CD3 ⁇ chains are highly related cell surface proteins of the immunoglobulin superfamily containing a single immunoglobulin domain.
  • the transmembrane regions of the CD3 ⁇ , CD3 ⁇ , and CD3 ⁇ chains are negatively charged, which is a characteristic that allows these chains to associate with the positively charged T cell receptor chains.
  • the intracellular tails of the CD3 ⁇ , CD3 ⁇ , and CD3 ⁇ chains each contain a single conserved motif known as an immunoreceptor tyrosine-based activation motif or ITAM, whereas each CD3 ⁇ chain has three. It is believed the ITAMs are important for the signaling capacity of a TCR complex.
  • CD3 as used in the present disclosure can be from various animal species, including human, monkey, mouse, rat, or other mammals.
  • a “conservative substitution” is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties.
  • exemplary conservative substitutions are well-known in the art (see, e.g., WO 97/09433, page 10, published Mar. 13, 1997; Lehninger, Biochemistry, Second Edition; Worth Publishers, Inc. NY:NY (1975), pp. 71-77; Lewin, Genes IV, Oxford University Press, NY and Cell Press, Cambridge, Mass. (1990), p. 8).
  • a conservative substitution includes a leucine to serine substitution.
  • derivative refers to a modification of one or more amino acid residues of a peptide by chemical or biological means, either with or without an enzyme, e.g., by glycosylation, alkylation, acylation, ester formation, or amide formation.
  • a polypeptide or amino acid sequence “derived from” a designated polypeptide or protein refers to the origin of the polypeptide.
  • the polypeptide or amino acid sequence which is derived from a particular sequence (sometimes referred to as the “starting” or “parent” or “parental” sequence) has an amino acid sequence that is essentially identical to the starting sequence or a portion thereof, wherein the portion consists of at least 10-20 amino acids, at least 20-30 amino acids, or at least 30-50 amino acids, or at least 50-150 amino acids, or which is otherwise identifiable to one of ordinary skill in the art as having its origin in the starting sequence.
  • Polypeptides derived from another polypeptide can have one or more mutations relative to the starting polypeptide, e.g., one or more amino acid residues which have been substituted with another amino acid residue or which has one or more amino acid residue insertions or deletions.
  • the polypeptide can comprise an amino acid sequence which is not naturally occurring. Such variations necessarily have less than 100% sequence identity or similarity with the starting polypeptide.
  • the variant will have an amino acid sequence from about 60% to less than 100% amino acid sequence identity or similarity with the amino acid sequence of the starting polypeptide.
  • the variant will have an amino acid sequence from about 75% to less than 100%, from about 80% to less than 100%, from about 85% to less than 100%, from about 90% to less than 100%, from about 95% to less than 100% amino acid sequence identity or similarity with the amino acid sequence of the starting polypeptide.
  • a position of an amino acid residue in a variable region of an immunoglobulin molecule is numbered according to the Kabat numbering convention (Kabat, Sequences of Proteins of Immunological Interest, 5 th ed. Bethesda, Md.: Public Health Service, National Institutes of Health (1991)), and a position of an amino acid residue in a constant region of an immunoglobulin molecule is numbered according to EU nomenclature (Ward et al., 1995 Therap. Immunol. 2:77-94).
  • the term “dimer” refers to a biological entity that consists of two subunits associated with each other via one or more forms of intramolecular forces, including covalent bonds (e.g., disulfide bonds) and other interactions (e.g., electrostatic interactions, salt bridges, hydrogen bonding, and hydrophobic interactions), and is stable under appropriate conditions (e.g., under physiological conditions, in an aqueous solution suitable for expressing, purifying, and/or storing recombinant proteins, or under conditions for non-denaturing and/or non-reducing electrophoresis).
  • a “heterodimer” or “heterodimeric protein,” as used herein, refers to a dimer formed from two different polypeptides.
  • a heterodimer does not include an antibody formed from four polypeptides (i.e., two light chains and two heavy chains).
  • a “hinge region” or a “hinge” refers to a polypeptide derived from (a) an interdomain region of a transmembrane protein (e.g., a type I transmembrane protein); or (b) a stalk region of a type II C-lectin.
  • a hinge region can be derived from an interdomain region of an immunoglobulin superfamily member; suitable hinge regions within this particular class include (i) immunoglobulin hinge regions (made up of, for example, upper and/or core region(s)) or functional variants thereof, including wild-type and altered immunoglobulin hinges, and (ii) regions (or functional variants thereof) that connect immunoglobulin V-like or immunoglobulin C-like domains.
  • a “wild-type immunoglobulin hinge region” refers to a naturally occurring upper and middle hinge amino acid sequences interposed between and connecting the CH1 and CH2 domains (for IgG, IgA, and IgD) or interposed between and connecting the CH1 and CH3 domains (for IgE and IgM) found in the heavy chain of an antibody.
  • a wild type immunoglobulin hinge region sequence is human, and can comprise a human IgG hinge region.
  • altered wild-type immunoglobulin hinge region refers to (a) a wild type immunoglobulin hinge region with up to 30% amino acid changes (e.g., up to 25%, 20%, 15%, 10%, or 5% amino acid substitutions or deletions), or (b) a portion of a wild type immunoglobulin hinge region that has a length of about 5 amino acids (e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids) up to about 120 amino acids (for instance, having a length of about 10 to about 40 amino acids or about 15 to about 30 amino acids or about 15 to about 20 amino acids or about 20 to about 25 amino acids), has up to about 30% amino acid changes (e.g., up to about 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1% amino acid substitutions or deletions or a combination thereof), and has an IgG core hinge region as disclosed in PCT/US2010/62436 and PCT/US
  • humanized refers to a process of making an antibody or immunoglobulin binding proteins and polypeptides derived from a non-human species (e.g., mouse or rat) less immunogenic to humans, while still retaining antigen-binding properties of the original antibody, using genetic engineering techniques.
  • the binding domain(s) of an antibody or immunoglobulin binding proteins and polypeptides e.g., light and heavy chain variable regions, Fab, scFv
  • Fab heavy chain variable regions
  • Non-human binding domains can be humanized using techniques known as CDR grafting (Jones et al., Nature 321:522 (1986)) and variants thereof, including “reshaping” (Verhoeyen, al., 1988 Science 239:1534-1536; Riechmann, et al., 1988 Nature 332:323-337; Tempest, et al., Bio/Technol 1991 9:266-271), “hyperchimerization” (Queen, et al., 1989 Proc Natl Acad Sci USA 86:10029-10033: Co, et al., 1991 Proc Natl Acad Sci USA 88:2869-2873; Co, et al., 1992 J Immunol 148:1149-1154), and “veneering” (Mark, et al., “Derivation of therapeutically active humanized and veneered anti-CD18 antibodies.
  • immunoglobulin dimerization domain or “immunoglobulin heterodimerization domain”, as used herein, refers to an immunoglobulin domain of a polypeptide chain that preferentially interacts or associates with a different immunoglobulin domain of a second polypeptide chain, wherein the interaction of the different immunoglobulin heterodimerization domains substantially contributes to or efficiently promotes heterodimerization of the first and second polypeptide chains (i.e., the formation of a dimer between two different polypeptide chains, which is also referred to as a “heterodimer”).
  • the interactions between immunoglobulin heterodimerization domains “substantially contributes to or efficiently promotes” the heterodimerization of first and second polypeptide chains if there is a statistically significant reduction in the dimerization between the first and second polypeptide chains in the absence of the immunoglobulin heterodimerization domain of the first polypeptide chain and/or the immunoglobulin heterodimerization domain of the second polypeptide chain.
  • immunoglobulin heterodimerization domains include an immunoglobulin CH1 domain, an immunoglobulin CL domain (e.g., C ⁇ or C ⁇ isotypes), or derivatives thereof, including wild type immunoglobulin CH1 and CL domains and altered (or mutated) immunoglobulin CH1 and CL domains, as provided therein.
  • an “immunoglobulin constant region” or “constant region” is a term defined herein to refer to a peptide or polypeptide sequence that corresponds to or is derived from part or all of one or more constant region domains.
  • the immunoglobulin constant region corresponds to or is derived from part or all of one or more constant region domains, but not all constant region domains of a source antibody.
  • the constant region comprises IgG CH2 and CH3 domains, e.g., IgG1 CH2 and CH3 domains.
  • the constant region does not comprise a CH1 domain.
  • the constant region domains making up the constant region are human.
  • the constant region domains of a fusion protein of this disclosure lack or have minimal effector functions of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement activation and complement-dependent cytotoxicity (CDC), while retaining the ability to bind some F C receptors (such as F C Rn, the neonatal Fc receptor) and retaining a relatively long half life in vivo.
  • a fusion protein of this disclosure includes constant domains that retain such effector function of one or both of ADCC and CDC.
  • a binding domain of this disclosure is fused to a human IgG1 constant region, wherein the IgG1 constant region has one or more of the following amino acids mutated: leucine at position 234 (L234), leucine at position 235 (L235), glycine at position 237 (G237), glutamate at position 318 (E318), lysine at position 320 (K320), lysine at position 322 (K322), or any combination thereof (numbering according to EU). For example, any one or more of these amino acids can be changed to alanine.
  • an IgG1 Fc domain has each of L234, L235, G237, E318, K320, and K322 (according to EU numbering) mutated to an alanine (i.e., L234A, L235A, G237A, E318A, K320A, and K322A, respectively), and optionally an N297A mutation as well (i.e., essentially eliminating glycosylation of the CH2 domain).
  • an alanine i.e., L234A, L235A, G237A, E318A, K320A, and K322A, respectively
  • Fc region or “Fc domain” refers to a polypeptide sequence corresponding to or derived from the portion of a source antibody that is responsible for binding to antibody receptors on cells and the C1q component of complement.
  • Fc stands for “fragment crystalline,” the fragment of an antibody that will readily form a protein crystal. Distinct protein fragments, which were originally described by proteolytic digestion, can define the overall general structure of an immunoglobulin protein. As originally defined in the literature, the Fc fragment consists of the disulfide-linked heavy chain hinge regions, CH2, and CH3 domains. However, more recently the term has been applied to a single chain consisting of CH3, CH2, and at least a portion of the hinge sufficient to form a disulfide-linked dimer with a second such chain.
  • Fc includes variants of naturally occurring sequences.
  • SMIP protein scaffold as generally disclosed in, for example, in US Patent Application Publication Nos. 2003/0133939, 2003/0118592, and 2005/0136049, which are incorporated herein by reference in their entirety.
  • PSMA-specific SMIP molecules or “SMIP molecules” described in the Examples and throughout the disclosure herein should be understood to be PSMA-binding proteins comprising SMIP scaffolding, e.g., in order from amino to carboxyl-terminus, a first binding domain, a hinge region, and an immunoglobulin constant region.
  • PIMS protein scaffold as generally disclosed in, for example, in US Patent Application Publication No. 2009/0148447, which is incorporated herein in its entirety by reference.
  • PSMA-specific PIMS molecules or “PIMS molecules” described in the Examples and throughout the disclosure herein should be understood to be PSMA-binding proteins comprising PIMS scaffolding, e.g., in order from amino to carboxyl-terminus, an immunoglobulin constant region, a hinge region and a first binding domain.
  • the term “Interceptor” is used to refer to a monospecific or multispecific heterodimeric protein scaffold as generally disclosed in PCT applications PCT/US2010/62436 and PCT/US2010/62404, which are incorporated herein in their entirety.
  • the “PSMA-specific Interceptor molecules” or “Interceptor molecules” described in the Examples and throughout the disclosure herein should be understood to be PSMA-binding proteins comprising Interceptor scaffolding, e.g., two non-identical polypeptide chains, each polypeptide chain comprising an immunoglobulin heterodimerization domain.
  • the interfacing immunoglobulin heterodimerization domains are different.
  • the immunoglobulin heterodimerization domain comprises a CH1 domain or a derivative thereof.
  • the immunoglobulin heterodimerization domain comprises a CL domain or a derivative thereof.
  • the CL domain is a C ⁇ or C ⁇ isotype or a derivative thereof.
  • SCORPION is a term used to refer to a multi-specific binding protein scaffold.
  • SCORPIONTM is a trademark of Emergent Product Development Seattle, LLC. Multi-specific binding proteins and polypeptides are disclosed, for instance, in PCT Application Publication No. WO 2007/146968, U.S. Patent Application Publication No. 2006/0051844, PCT Application Publication No, WO 2010/040105, PCT Application Publication No. WO 2010/003108, and U.S. Pat. No. 7,166,707, which are incorporated herein by reference in their entirety.
  • a SCORPION polypeptide comprises two binding domains (the domains can be designed to specifically bind the same or different targets), two hinge regions, and an immunoglobulin constant region.
  • SCORPION proteins are homodimeric proteins comprising two identical, disulfide-bonded SCORPION polypeptides.
  • PSMA-specific SCORPION molecules or “SCORPION molecules” described in the Examples and throughout the disclosure herein should be understood to be PSMA-binding proteins comprising SCORPION scaffolding, e.g., two binding domains (the domains can be designed to specifically bind the same or different targets), two hinge regions, and an immunoglobulin constant region.
  • the “stalk region” of a type II C-lectin refers to the portion of the extracellular domain of the type II C-lectin that is located between the C-type lectin-like domain (CTLD; e.g., similar to CTLD of natural killer cell receptors) and the transmembrane domain.
  • C-type lectin-like domain C-type lectin-like domain
  • the extracellular domain corresponds to amino acid residues 34-179
  • the CTLD corresponds to amino acid residues 61-176.
  • the stalk region of the human CD94 molecule includes amino acid residues 34-60, which is found between the membrane and the CTLD (see Boyington et al., Immunity 10:75, 1999; for descriptions of other stalk regions, see also Beavil et al., Proc. Nat'l. Acad. Sci. USA 89:753, 1992; and Figdor et al., Nature Rev. Immunol. 2:77, 2002).
  • These type II C-lectins can also have from six to 10 junction amino acids between the stalk region and the transmembrane region or the CTLD.
  • the 233 amino acid human NKG2A protein GenBank Accession No. P26715.1, PRI Jun.
  • CTLD transmembrane domain ranging from amino acids 71-93 and an extracellular domain ranging from amino acids 94-233.
  • the CTLD is comprised of amino acids 119-231, and the stalk region comprises amino acids 99-116, which is flanked by junctions of five and two amino acids.
  • Other type II C-lectins, as well as their extracellular ligand-bind domains, interdomain or stalk regions, and CTLDs are known in the art (see, e.g., GenBank Accession Nos. NP — 001993.2; AAH07037.1, PRI Jul. 15, 2006; NP — 001773.1, PRI Jun. 20, 1010; AAL65234.1, PRI Jan. 17, 2002, and CAA04925.1, PRI Nov. 14, 2006, for the sequences of human CD23, CD69, CD72, NKG2A and NKG2D and their descriptions, respectively).
  • interdomain region of a transmembrane protein refers to a portion of the extracellular domain of the transmembrane protein that is located between two adjacent domains.
  • interdomain regions include regions linking adjacent Ig domains of immunoglobulin superfamily members (e.g., an immunoglobulin hinge region from IgG, IgA, IgD, or IgE; the region linking the IgV and IgC2 domains of CD2; or the region linking the IgV and IgC domains of CD80 or CD86).
  • Another example of an interdomain region is the region linking the non-Ig and IgC2 domain of CD22, a type I sialic acid-binding Ig-like lectin.
  • a polypeptide region “derived from” a stalk region of a type II C-lectin, or “derived from” a transmembrane protein interdomain region refers to an about five to about 150 amino acid sequence, an about 5 to about 100 amino acid sequence, an about 5 to about 50 amino acid sequence, an about 5 to about 40 amino acid sequence, an about 5 to about 30 amino acid sequence, an about 5 to about 25 amino acid sequence, an about 5 to about 20 amino acid sequence, an about 10 to about 25 amino acid sequence, an about 10 to about 20 amino acid sequence, about 8 to about 20 amino acid sequence, about 9 to about 20 amino acid sequence, about 10 to about 20 amino acid sequence, about 11 to about 20 amino acid sequence, about 12 to about 20 amino acid sequence, about 13 to about 20 amino acid sequence, about 14 to about 20 amino acid sequence, about 15 to about 20 amino acid sequence, or an about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid sequence, wherein all or at least a portion of which includes (
  • a derivative of a stalk region is more resistant to proteolytic cleavage as compared to the wild-type stalk region sequence, such as those derived from about eight to about 20 amino acids of NKG2A, NKG2D, CD23, CD64, CD72, or CD94.
  • junction amino acids refers to one or more (e.g., about 2-10) amino acid residues between two adjacent regions or domains of a polypeptide, such as between a hinge and an adjacent immunoglobulin constant region or between a hinge and an adjacent binding domain or between a peptide linker that links two immunoglobulin variable domains and an adjacent immunoglobulin variable domain.
  • Junction amino acids can result from the construct design of a polypeptide (e.g., amino acid residues resulting from the use of a restriction enzyme site during the construction of a nucleic acid molecule encoding a polypeptide).
  • a “linker between CH3 and CH1 or CL” refers to one or more (e.g., about 2-12, about 2-10, about 4-10, about 5-10, about 6-10, about 7-10, about 8-10, about 9-10, about 8-12, about 9-12, or about 10-12) amino acid residues between the C-terminus of a CH3 domain (e.g., a wild type CH3 or a mutated CH3) and the N-terminus of a CH1 domain or CL domain (e.g., Ck).
  • a CH3 domain e.g., a wild type CH3 or a mutated CH3
  • Ck the N-terminus of a CH1 domain or CL domain
  • the term “patient in need” refers to a patient at risk of, or suffering from, a disease, disorder or condition that is amenable to treatment or amelioration with a PSMA-binding protein or polypeptide or a composition thereof provided herein.
  • peptide linker refers to an amino acid sequence that connects a heavy chain variable region to a light chain variable region and provides a spacer function compatible with interaction of the two sub-binding domains so that the resulting polypeptide retains a specific binding affinity to the same target molecule as an antibody that comprises the same light and heavy chain variable regions.
  • a linker is comprised of five to about 35 amino acids, for instance, about 15 to about 25 amino acids.
  • the term “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce allergic or other serious adverse reactions when administered using routes well known in the art. Molecular entities and compositions approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans are considered to be “pharmaceutically acceptable.”
  • promoter refers to a region of DNA involved in binding RNA polymerase to initiate transcription.
  • nucleic acid refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the terms encompass nucleic acids containing analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated.
  • degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al. (1991) Nucleic Acid Res. 19:5081; Ohtsuka et al. (1985) J. Biol. Chem. 260:2605-2608; Cassol et al. (1992); Rossolini et al. (1994) Mol. Cell. Probes 8:91-98).
  • nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.
  • nucleic acid As used herein, the terms “nucleic acid,” “nucleic acid molecule,” or “polynucleotide” are intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof.
  • DNA molecules e.g., cDNA or genomic DNA
  • RNA molecules e.g., mRNA
  • analogs of the DNA or RNA generated using nucleotide analogs e.g., mRNA
  • expression refers to the biosynthesis of a product encoded by a nucleic acid.
  • expression involves transcription of the nucleic acid segment into mRNA and the translation of mRNA into one or more polypeptides.
  • expression unit and “expression cassette” are used interchangeably herein and denote a nucleic acid segment encoding a polypeptide of interest and capable of providing expression of the nucleic acid segment in a host cell.
  • An expression unit typically comprises a transcription promoter, an open reading frame encoding the polypeptide of interest, and a transcription terminator, all in operable configuration.
  • an expression unit can further include other nucleic acid segments such as, e.g., an enhancer or a polyadenylation signal.
  • expression vector refers to a nucleic acid molecule, linear or circular, comprising one or more expression units.
  • an expression vector can also include additional nucleic acid segments such as, for example, one or more origins of replication or one or more selectable markers.
  • Expression vectors are generally derived from plasmid or viral DNA, or can contain elements of both.
  • sequence identity refers to a relationship between two or more polynucleotide sequences or between two or more polypeptide sequences. When a position in one sequence is occupied by the same nucleic acid base or amino acid residue in the corresponding position of the comparator sequence, the sequences are said to be “identical” at that position.
  • the percentage “sequence identity” is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of “identical” positions.
  • the number of “identical” positions is then divided by the total number of positions in the comparison window and multiplied by 100 to yield the percentage of “sequence identity.” Percentage of “sequence identity” is determined by comparing two optimally aligned sequences over a comparison window.
  • the comparison window for nucleic acid sequences can be, for instance, at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 or more nucleic acids in length.
  • the comparison windon for polypeptide sequences can be, for instance, at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300 or more amino acids in length.
  • the portion of a polynucleotide or polypeptide sequence in the comparison window can comprise additions or deletions termed gaps while the reference sequence is kept constant.
  • An optimal alignment is that alignment which, even with gaps, produces the greatest possible number of “identical” positions between the reference and comparator sequences. Percentage “sequence identity” between two sequences can be determined using the version of the program “BLAST 2 Sequences” which was available from the National Center for Biotechnology Information as of Sep.
  • Two nucleotide or amino acid sequences are considered to have “substantially similar sequence identity” or “substantial sequence identity” if the two sequences have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity relative to each other.
  • polypeptide or “polypeptide chain” is a single, linear and contiguous arrangement of covalently linked amino acids. It does not include two polypeptide chains that link together in a non-linear fashion, such as via an interchain disulfide bond (e.g., a half immunoglobulin molecule in which a light chain links with a heavy chain via a disulfide bond). Polypeptides can have or form one or more intrachain disulfide bonds. With regard to polypeptides as described herein, reference to amino acid residues corresponding to those specified by SEQ ID NO includes post-translational modifications of such residues.
  • a “protein” is a macromolecule comprising one or more polypeptide chains.
  • a protein can also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents can be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.
  • small modular immunopharmaceutical proteins refers to a protein scaffold generally disclosed, for instance, U.S. Patent Publication Nos. 2003/0133939, 2003/0118592, and 2005/0136049.
  • SMIPTM is a trademark of Emergent Product Development Seattle LLC.
  • a SMIP protein can comprise a polypeptide chain having a binding domain, a hinge region and an immunoglobulin constant region.
  • amino-terminal and “carboxyl-terminal” are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl-terminus of the reference sequence, but is not necessarily at the carboxyl-terminus of the complete polypeptide.
  • T cell receptor is a molecule found on the surface of T cells that, along with CD3, is generally responsible for recognizing antigens bound to major histocompatibility complex (MHC) molecules. It consists of a disulfide-linked heterodimer of the highly variable ⁇ and ⁇ chains in most T cells. In other T cells, an alternative receptor made up of variable ⁇ and ⁇ chains is expressed.
  • MHC major histocompatibility complex
  • Each chain of the TCR is a member of the immunoglobulin superfamily and possesses one N-terminal immunoglobulin variable domain, one immunoglobulin constant domain, a transmembrane region, and a short cytoplasmic tail at the C-terminal end (see Abbas and Lichtman, Cellular and Molecular Immunology (5th Ed.), Editor: Saunders, Philadelphia, 2003; Janeway et al., Immunobiology: The Immune System in Health and Disease, 4 th Ed., Current Biology Publications, p 148, 149, and 172, 1999).
  • TCR as used in the present disclosure can be from various animal species, including human, mouse, rat, or other mammals.
  • TCR complex refers to a complex formed by the association of CD3 chains with other TCR chains.
  • a TCR complex can be composed of a CD3 ⁇ chain, a CD3 ⁇ chain, two CD3 ⁇ chains, a homodimer of CD3 ⁇ chains, a TCR ⁇ chain, and a TCR ⁇ chain.
  • a TCR complex can be composed of a CD3 ⁇ chain, a CD3 ⁇ chain, two CD3 ⁇ chains, a homodimer of CD3 ⁇ chains, a TCR ⁇ chain, and a TCR ⁇ chain.
  • a component of a TCR complex refers to a TCR chain (i.e., TCR ⁇ , TCR ⁇ , TCR ⁇ or TCR ⁇ ), a CD3 chain (i.e., CD3 ⁇ , CD3 ⁇ , CD3 ⁇ or CD3 ⁇ , or a complex formed by two or more TCR chains or CD3 chains (e.g., a complex of TCR ⁇ and TCR ⁇ , a complex of TCR ⁇ and TCR ⁇ , a complex of CD3 ⁇ and CD3 ⁇ , a complex of CD3 ⁇ and CD3 ⁇ , or a sub-TCR complex of TCR ⁇ , TCR ⁇ , CD3 ⁇ , CD3 ⁇ , and two CD3 ⁇ chains).
  • Antibody-dependent cell-mediated cytotoxicity and “ADCC,” as used herein, refer to a cell-mediated process in which nonspecific cytotoxic cells that express Fc ⁇ Rs (e.g., monocytic cells such as Natural Killer (NK) cells and macrophages) recognize bound antibody (or other protein capable of binding Fc ⁇ Rs) on a target cell and subsequently cause lysis of the target cell.
  • Fc ⁇ Rs e.g., monocytic cells such as Natural Killer (NK) cells and macrophages
  • NK cells which express only Fc ⁇ RIII
  • monocytes depending on their state of activation, localization, or differentiation, can express Fc ⁇ RI, Fc ⁇ RII, and Fc ⁇ RIII.
  • ADCC activity means that the polypeptide or protein (for example, one comprising an immunoglobulin hinge region and an immunoglobulin constant region having CH2 and CH3 domains, such as derived from IgG (e.g., IgG1)), is capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) through binding of a cytolytic Fc receptor (e.g., Fc ⁇ RIII) on a cytolytic immune effector cell expressing the Fc receptor (e.g., an NK cell).
  • a cytolytic Fc receptor e.g., Fc ⁇ RIII
  • Complement-dependent cytotoxicity and “CDC,” as used herein, refer to a process in which components in normal serum (“complement”), together with an antibody or other C1q-complement-binding protein bound to a target antigen, exhibit lysis of a target cell expressing the target antigen.
  • Complement consists of a group of serum proteins that act in concert and in an orderly sequence to exert their effect.
  • classical complement pathway and “classical complement system,” as used herein, are synonymous and refer to a particular pathway for the activation of complement.
  • the classical pathway requires antigen-antibody complexes for initiation and involves the activation, in an orderly fashion, of nine major protein components designated C1 through C9.
  • the product is an enzyme that catalyzes the subsequent step. This cascade provides amplification and activation of large amounts of complement by a relatively small initial signal.
  • CDC activity means that the polypeptide or protein (for example, one comprising an immunoglobulin hinge region and an immunoglobulin constant region having CH2 and CH 3 domains, such as derived from IgG (e.g., IgG1)) is capable of mediating complement-dependent cytotoxicity (CDC) through binding of C1q complement protein and activation of the classical complement system.
  • Redirected T-cell cytotoxicity and “RTCC,” as used herein, refer to a T-cell-mediated process in which a cytotoxic T-cell is recruited to a target cell using a multi-specific protein that is capable of specifically binding both the cytotoxic T-cell and the target cell, and whereby a target-dependent cytotoxic T-cell response is elicited against the target cell.
  • Neovascularization and angiogenesis refer to the generation of new blood vessels into cells, tissue, or organs.
  • the control of angiogenesis is typically altered in certain disease states and, in many case, the pathological damage associated with the disease is related to altered or unregulated angiogenesis.
  • Persistant, unregulated angiogenesis occurs in a variety of disease states, including those characterized by the abnormal growth by endothelial cells, and supports the pathological damage seen in these conditions including leakage and permeability of blood vessels.
  • vascular disorder refers to any disease or disorder having a pathology that is mediated, at least in part, by increased or unregulated angiogenesis activity.
  • diseases or disorders include various cancers comprising solid tumors.
  • Such diseases or disorders comprising a vasculature characterized by PSMA overexpression e.g., certain cancers comprising solid tumors, such as clear cell renal carcinoma, colorectal cancer, bladder cancer, and lung cancer
  • PSMA overexpression are particularly amenable to certain treatment methods for inhibition angiogenesis, as described further herein.
  • treatment refers to either a therapeutic treatment or prophylactic/preventative treatment.
  • a treatment is therapeutic if at least one symptom of disease in an individual receiving treatment improves or a treatment can delay worsening of a progressive disease in an individual, or prevent onset of additional associated diseases.
  • a therapeutically effective amount (or dose)” or “effective amount (or dose)” of a specific binding molecule or compound refers to that amount of the compound sufficient to result in amelioration of one or more symptoms of the disease being treated in a statistically significant manner.
  • a therapeutically effective dose refers to that ingredient alone.
  • a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered serially or simultaneously (in the same formulation or concurrently in separate formulations).
  • the term “transformation,” “transfection,” and “transduction” refer to the transfer of nucleic acid (i.e., a nucleotide polymer) into a cell.
  • the term “genetic transformation” refers to the transfer and incorporation of DNA, especially recombinant DNA, into a cell.
  • the transferred nucleic acid can be introduced into a cell via an expression vector.
  • variants refers to a nucleic acid or polypeptide differing from a reference nucleic acid or polypeptide, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the reference nucleic acid or polypeptide. For instance, a variant may exhibit at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% sequence identity compared to the active portion or full length reference nucleic acid or polypeptide.
  • variable region also referred to as “light chain variable domain” or “VL” and “heavy chain variable region” (also referred to as “heavy chain variable domain” or “VH”) refer to the variable binding region from an antibody light and heavy chain, respectively.
  • the variable binding regions are made up of discrete, well-defined sub-regions known as “complementarity determining regions” (CDRs) and “framework regions” (FRs). In one embodiment, the FRs are humanized.
  • CDRs complementarity determining regions
  • FRs framework regions
  • the FRs are humanized.
  • CL refers to an “immunoglobulin light chain constant region” or a “light chain constant region,” i.e., a constant region from an antibody light chain.
  • CH refers to an “immunoglobulin heavy chain constant region” or a “heavy chain constant region,” which is further divisible, depending on the antibody isotype into CH1, CH2, and CH3 (IgA, IgD, IgG), or CH1, CH2, CH3, and CH4 domains (IgE, IgM).
  • a “Fab” fragment antigen binding is the part of an antibody that binds to antigens and includes the variable region and CH1 domain of the heavy chain linked to the light chain via an inter-chain disulfide bond.
  • the present disclosure provides polypeptides and proteins comprising binding domains, in particular, a first binding domain that specifically binds PSMA.
  • the polypeptides and proteins comprising binding domains of this disclosure can further comprise immunoglobulin constant regions, linker peptides, hinge regions, immunoglobulin dimerization/heterodimerization domains, junctional amino acids, tags, etc. These components of the disclosed polypeptides and proteins are described in further detail below.
  • the PSMA-binding polypeptides and proteins disclosed herein can be in the form of an antibody or a fusion protein of any of a variety of different formats (e.g., the fusion protein can be in the form of a SMIP molecule, a PIMS molecule, a SCORPION molecule or an Interceptor molecule).
  • a PSMA-binding protein in accordance with the present invention generally includes at least one PSMA-binding polypeptide chain comprising (a) a PSMA-binding domain as set forth herein.
  • the PSMA-binding polypeptide further includes (b) a hinge region carboxyl-terminal to the PSMA-binding domain, and (c) an immunoglobulin constant region (e.g., a SMIP molecule).
  • the PSMA-binding polypeptide further includes (d) a second hinge region carboxyl-terminal to the immunoglobulin constant region, and (e) a second binding domain carboxyl-terminal to the second hinge region (e.g., a SCORPION polypeptide).
  • the PSMA-binding polypeptide comprises (b) a hinge region amino-terminal to the PSMA-binding domain, and (c) an immunoglobulin sub-region amino-terminal to the hinge region (e.g., a PIMS polypeptide).
  • PSMA-binding polypeptides of the above formats are capable of homodimerization, typically through disulfide bonding, via the immunoglobulin constant region and/or hinge region (e.g., via an immunoglobulin constant region comprising IgG CH2 and CH3 domains and an IgG hinge region).
  • the immunoglobulin constant region and/or hinge region e.g., via an immunoglobulin constant region comprising IgG CH2 and CH3 domains and an IgG hinge region.
  • two identical PSMA-binding polypeptides homodimerize to form a dimeric PSMA-binding protein.
  • a PSMA-binding polypeptide further includes a heterodimerization domain that is capable of heterodimerization with a different heterodimerization domain in a second, non-identical polypeptide chain.
  • the second polypeptide chain for heterodimerization includes a second binding domain. Accordingly, in certain embodiments of the present invention, two non-identical polypeptide chains, one comprising the PSMA-binding domain and the second optionally comprising a second binding domain, dimerize to form a heterodimeric PSMA-binding protein.
  • PSMA-binding polypeptides, proteins, and their various components are further described herein below.
  • an immunoglobulin binding polypeptide of the present disclosure comprises a binding domain that specifically binds PSMA.
  • the PSMA-binding domain is capable of competing for binding to PSMA with an antibody having V L and V H regions having amino acid sequences as shown in SEQ ID NO:5 and SEQ ID NO:2, respectively (e.g., mAb 107-1A4), or with a single-chain Fv (scFv) having an amino acid sequence as shown in SEQ ID NO:21.
  • the PSMA-binding domain comprises (i) an immunoglobulin light chain variable region (V L ) comprising CDRs LCDR1, LCDR2, and LCDR3, and (ii) an immunoglobulin heavy chain variable region (V H ) comprising CDRs HCDR1, HCDR2, and HCDR3.
  • Suitable PSMA-binding domains include those having V L and V H regions derived from mAb 107-1A4.
  • LCDR3 has the amino acid sequence set forth in SEQ ID NO:17 and/or HCDR3 has the amino acid sequence set forth in SEQ ID NO:11; and LCDR1 and LCDR2 optionally have the amino acid sequences as set forth in SEQ ID NO:15 and SEQ ID NO:16, respectively, and HCDR1 and HCDR2 optionally have the amino acid sequences as set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively.
  • LCDR1, LCDR2, and LCDR3 have the amino acid sequences respectively shown in SEQ ID NOs:15, 16, and 17; and/or HCDR1, HCDR2, and HCDR3 have the amino acid sequences as respectively shown in SEQ ID NOs:9, 10, and 11.
  • a PSMA-binding protein can comprise one or more additional binding domains (e.g., second binding domain) that bind a target other than PSMA.
  • additional binding domains e.g., second binding domain
  • target molecules can comprise, for example, a particular cytokine or a molecule that targets the binding domain polypeptide to a particular cell type, a toxin, an additional cell receptor, an antibody, etc.
  • a binding domain for instance, as part of an Interceptor or SCORPION molecule, can comprise a TCR binding domain for recruitment of T cells to target cells expressing PSMA.
  • a polypeptide heterodimer as described herein can comprise a binding domain that specifically binds a TCR complex or a component thereof (e.g., TCR ⁇ , TCR ⁇ , CD3 ⁇ , CD3 ⁇ , and CD3 ⁇ ) and another binding domain that specifically binds to PSMA.
  • anti-CD3 antibodies from which the binding domain of this disclosure can be derived include CRIS-7 monoclonal antibody (Reinherz, E. L. et al. (eds.), Leukocyte typing II ., Springer Verlag, New York, (1986); V L and V H amino acid sequences respectively shown in SEQ ID NO:153
  • OKT3 ala-ala also referred to as OKT3 AA-FL or OKT3 FL
  • a humanized, Fc variant with alanine substitutions at positions 234 and 235 (Herold et al. (2003) J. Clin. Invest. 11:409); visilizumab (Carpenter et al. (2002) Blood 99:2712), G19-4 monoclonal antibody (Ledbetter et al., 1986, J. Immunol. 136:3945) and 145-2C11 monoclonal antibody (Hirsch et al. (1988) J. Immunol. 140: 3766).
  • An exemplary anti-TCR antibody is the BMA031 monoclonal antibody (Borst et al. (1990) Human Immunology 29:175-188).
  • a binding domain is a single-chain Fv fragment (scFv) that comprises V H and V L regions specific for a target of interest.
  • scFv single-chain Fv fragment
  • the V H and V L regions are human.
  • a PSMA-binding domain comprises or is a scFv that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or 100% identical to an amino acid sequence of a scFv of SEQ ID NO: 19, 21, 30, 31, 34 or 35.
  • a PSMA-binding domain comprises or is a sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or 100% identical to an amino acid sequence of a light chain variable region (V L ) (e.g., SEQ ID NO:23) or to a heavy chain variable region (V H ) (e.g., SEQ ID NO:25 or SEQ ID NO:27), or both.
  • V L light chain variable region
  • V H heavy chain variable region
  • each CDR comprises no more than one, two, or three substitutions, insertions or deletions, as compared to that from a monoclonal antibody or fragment or derivative thereof that specifically binds to a target of interest (e.g., PSMA).
  • a target of interest e.g., PSMA
  • the second binding domain competes for binding to CD3 ⁇ with the CRIS-7 or HuM291 monoclonal antibody.
  • the CD3-binding domain comprises an immunoglobulin light chain variable region (V L ) and an immunoglobulin heavy chain variable region (V H ) derived from the CRIS-7 or HuM291 monoclonal antibody (e.g., the V L and V H of the second binding domain can be humanized variable regions comprising, respectively, the light chain CDRs and the heavy chain CDRs of the monoclonal antibody).
  • the V L and V H regions derived from CRIS-7 can be selected from (a) a V L region comprising an amino acid sequence that is at least 95% identical or 100% to the amino acid sequence set forth in residues 139-245 of SEQ ID NO:47 and a V H region comprising an amino acid sequence that is at least 95% identical or 100% to the amino acid sequence set forth in residues 1-122 of SEQ ID NO:47; and (b) a V L region comprising an amino acid sequence that is at least 95% identical or 100% identical to the amino acid sequence set forth in residues 634-740 of SEQ ID NO:78 and a V H region comprising an amino acid sequence that is at least 95% or 100% identical to the amino acid sequence set forth in residues 496-616 of SEQ ID NO:78.
  • a binding domain V L and/or V H region of the present disclosure is derived from a V L and/or V H of a known monoclonal antibody (e.g., 107-1A4, CRIS-7, or HuM291) and contains about one or more (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10) insertions, about one or more (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10) deletions, about one or more (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions (e.g., conservative amino acid substitutions or non-conservative amino acid substitutions), or a combination of the above-noted changes, when compared with the V L and/or V H of a known monoclonal antibody.
  • a known monoclonal antibody e.g., 107-1A4, CRIS-7, or HuM291
  • amino acid substitutions e.g., conservative amino acid substitutions or non-conservative amino acid substitutions
  • the insertion(s), deletion(s) or substitution(s) can be anywhere in the V L and/or V H region, including at the amino- or carboxyl-terminus or both ends of this region, provided that each CDR comprises zero changes or at most one, two, or three changes and provided a binding domain containing the modified V L and/or V H region can still specifically bind its target with an affinity similar to the wild type binding domain.
  • the binding domain is a single-chain Fv (scFv) comprising immunoglobulin V L and V H regions joined by a peptide linker.
  • scFv single-chain Fv
  • a widely used peptide linker is a 15mer consisting of three repeats of a Gly-Gly-Gly-Gly-Ser amino acid sequence ((Gly 4 Ser) 3 ) (SEQ ID NO:152).
  • Other linkers have been used, and phage display technology, as well as selective infective phage technology, has been used to diversify and select appropriate linker sequences (Tang et al., J. Biol.
  • Other suitable linkers can be obtained by optimizing a simple linker (e.g., (Gly 4 Ser) n ) through random mutagenesis.
  • a binding domain comprises humanized immunoglobulin V L and/or V H regions.
  • Techniques for humanizing immunoglobulin V L and V H regions are known in the art and are discussed, for example, in United States Patent Application Publication No. 2006/0153837.
  • “Humanization” is expected to result in an antibody that is less immunogenic, with complete retention of the antigen-binding properties of the original molecule. In order to retain all of the antigen-binding properties of the original antibody, the structure of its antigen binding site should be reproduced in the “humanized” version.
  • humanization by CDR grafting involves recombining only the CDRs of a non-human antibody onto a human variable region framework and a human constant region. Theoretically, this should substantially reduce or eliminate immunogenicity (except if allotypic or idiotypic differences exist). However, it has been reported that some framework residues of the original antibody also may need to be preserved (Reichmann et al., Nature, 332:323 (1988); Queen et al., Proc. Natl. Acad. Sci. USA, 86:10,029 (1989)).
  • framework residues that need to be preserved are amenable to identification through computer modeling.
  • critical framework residues can potentially be identified by comparing known antigen-binding site structures (Padlan, Molec. Immunol., 31(3):169-217 (1994), incorporated herein by reference).
  • the residues that potentially affect antigen binding fall into several groups.
  • the first group comprises residues that are contiguous with the antigen site surface, which could therefore make direct contact with antigens. These residues include the amino-terminal residues and those adjacent to the CDRs.
  • the second group includes residues that could alter the structure or relative alignment of the CDRs, either by contacting the CDRs or another peptide chain in the antibody.
  • the third group comprises amino acids with buried side chains that could influence the structural integrity of the variable domains.
  • the residues in these groups are usually found in the same positions (Padlan, 1994, supra) although their positions as identified may differ depending on the numbering system (see Kabat et al., “Sequences of proteins of immunological interest, 5th ed., Pub. No. 91-3242, U.S. Dept. Health & Human Services, NIH, Bethesda, Md., 1991).
  • a hinge is a wild-type human immunoglobulin hinge region.
  • one or more amino acid residues can be added at the amino- or carboxyl-terminus of a wild type immunoglobulin hinge region as part of a fusion protein construct design.
  • additional junction amino acid residues at the hinge amino-terminus can be “RT,” “RSS,” “TG,” or “T,” or at the hinge carboxyl-terminus can be “Sc”, or a hinge deletion can be combined with an addition, such as ⁇ P with “SG” added at the carboxyl-terminus.
  • a hinge is an altered immunoglobulin hinge in which one or more cysteine residues in a wild type immunoglobulin hinge region is substituted with one or more other amino acid residues (e.g., serine or alanine).
  • Exemplary altered immunoglobulin hinges include an immunoglobulin human IgG1 hinge region having one, two or three cysteine residues found in a wild type human IgG1 hinge substituted by one, two or three different amino acid residues (e.g., serine or alanine).
  • An altered immunoglobulin hinge can additionally have a proline substituted with another amino acid (e.g., serine or alanine).
  • the above-described altered human IgG1 hinge can additionally have a proline located carboxyl-terminal to the three cysteines of wild type human IgG1 hinge region substituted by another amino acid residue (e.g., serine, alanine).
  • the prolines of the core hinge region are not substituted.
  • a hinge polypeptide comprises or is a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a wild type immunoglobulin hinge region, such as a wild type human IgG1 hinge, a wild type human IgG2 hinge, or a wild type human IgG4 hinge.
  • a hinge present in a PSMA-binding polypeptide can be a hinge that is not based on or derived from an immunoglobulin hinge (i.e., not a wild-type immunoglobulin hinge or an altered immunoglobulin hinge).
  • immunoglobulin hinge i.e., not a wild-type immunoglobulin hinge or an altered immunoglobulin hinge.
  • Examples for such hinges include peptides of about five to about 150 amino acids derived from an interdomain region of a transmembrane protein or stalk region of a type II C-lectin, for instance, peptides of about eight to 25 amino acids and peptides of about seven to 18 amino acids.
  • interdomain or stalk region hinges have seven to 18 amino acids and can form an ⁇ -helical coiled coil structure. In certain embodiments, interdomain or stalk region hinges contain 0, 1, 2, 3, or 4 cysteines. Exemplary interdomain or stalk region hinges are peptide fragments of the interdomain or stalk regions, such as ten to 150 amino acid fragments from the stalk regions of CD69, CD72, CD94, NKG2A and NKG2D.
  • hinge sequences have about 5 to 150 amino acids, 5 to 10 amino acids, 10 to 20 amino acids, 20 to 30 amino acids, 30 to 40 amino acids, 40 to 50 amino acids, 50 to 60 amino acids, 5 to 60 amino acids, 5 to 40 amino acids, 8 to 20 amino acids, or 10 to 15 amino acids.
  • the hinge can be primarily flexible, but can also provide more rigid characteristics or can contain primarily ⁇ -helical structure with minimal ⁇ -sheet structure.
  • the lengths or the sequences of the hinges can affect the binding affinities of the binding domains to which the hinges are directly or indirectly (via another region or domain, such as an heterodimerization domain) connected as well as one or more activities of the Fc region portions to which the hinges are directly or indirectly connected.
  • hinge sequences are stable in plasma and serum and are resistant to proteolytic cleavage.
  • the first lysine in the IgG1 upper hinge region can be mutated to minimize proteolytic cleavage, for instance, the lysine can be substituted with methionine, threonine, alanine or glycine, or is deleted.
  • the PSMA-binding polypeptide is capable of forming a heterodimer with a second polypeptide chain and comprises a hinge region (a) immediately amino-terminal to an immunoglobulin constant region (e.g., amino-terminal to a CH2 domain wherein the immunoglobulin constant region includes CH2 and CH3 domains, or amino-terminal to a CH3 domain wherein the immunoglobulin sub-regions includes CH3 and CH4 domains), (b) interposed between and connecting a binding domain (e.g., scFv) and a immunoglobulin heterodimerization domain, (c) interposed between and connecting a immunoglobulin heterodimerization domain and an immunoglobulin constant region (e.g., wherein the immunoglobulin constant region includes CH2 and CH3 domains or CH3 and CH4 domains), (d) interposed between and connecting an immunoglobulin constant region and a binding domain, (e) at the amino-terminus of a poly
  • a polypeptide chain comprising a hinge region as described herein will be capable of associating with a different polypeptide chain to form a heterodimeric protein provided herein, and the heterodimer formed will contain a binding domain that retains its target specificity or its specific target binding affinity.
  • a hinge present in a polypeptide that forms a heterodimer with another polypeptide chain can be an immunoglobulin hinge, such as a wild-type immunoglobulin hinge region or an altered immunoglobulin hinge region thereof.
  • a hinge of one polypeptide chain of a heterodimeric protein is identical to a corresponding hinge of the other polypeptide chain of the heterodimer.
  • a hinge of one chain is different from that of the other chain (in their length or sequence).
  • a heterodimeric protein has a CD3- or TCR-binding domain in one chain and a PSMA-binding domain in another chain. Having two different hinges in the two chains may allow the heterodimer to bind to the PSMA first, and then to a CD3 or other TCR component second. Thus, the heterodimer may recruit CD3 + T cells to PSMA-expressing cells (e.g., PSMA-expressing tumor cells), which in turn may damage or destroy the PSMA-expressing cells.
  • PSMA-expressing cells e.g., PSMA-expressing tumor cells
  • Exemplary hinge regions suitable for use in accordance with the present invention are shown in the Tables 1 and 2 below. Additional exemplary hinge regions are set forth in SEQ ID NOs: 241-244, 601, 78, 763-791, 228, 379-434, 618-749 of WO2011/090762 (said sequences incorporated by reference herein).
  • a PSMA-binding polypeptide or protein of the invention can comprise an “immunoglobulin dimerization domain” or “immunoglobulin heterodimerization domain.”
  • immunoglobulin dimerization domain or “immunoglobulin heterodimerizatior domain,” as used herein, refers to an immunoglobulin domain of a polypeptide chain that preferentially interacts or associates with a different immunoglobulin domain of another polypeptide chain, wherein the interaction of the different immunoglobulin heterodimerization domains substantially contributes to or efficiently promotes heterodimerization of the first and second polypeptide chains (i.e., the formation of a dimer between two different polypeptide chains, which is also referred to as a “heterodimer” or “heterodimeric protein”).
  • the interactions between immunoglobulin heterodimerization domains “substantially contributes to or efficiently promotes” the heterodimerization of first and second polypeptide chains if there is a statistically significant reduction in the dimerization between the first and second polypeptide chains in the absence of the immunoglobulin heterodimerization domain of the first polypeptide chain and/or the immunoglobulin heterodimerization domain of the second polypeptide chain.
  • immunoglobulin heterodimerization domains include an immunoglobulin CH1 domain, an immunoglobulin CL1 domain (e.g., C ⁇ or C ⁇ isotypes), or derivatives thereof, including wild-type immunoglobulin CH1 and CL domains and altered (or mutated) immunoglobulin CH1 and CL domains, such as provided herein.
  • Dimerization/heterodimerization domains can be used where it is desired to form heterodimers from two non-identical polypeptide chains, where one or both polypeptide chains comprises a binding domain.
  • one polypeptide chain member of certain heterodimers described herein does not contain a binding domain.
  • a heterodimeric protein of the present disclosure comprises an immunoglobulin heterodimerization domain in each polypeptide chain.
  • the immunoglobulin heterodimerization domains in the polypeptide chains of a heterodimer are different from each other and thus can be differentially modified to facilitate heterodimerization of both chains and to minimize homodimerization of either chain.
  • immunoglobulin heterodimerization domains provided herein allow for efficient heterodimerization between different polypeptides and facilitate purification of the resulting heterodimeric protein.
  • immunoglobulin heterodimerization domains useful for promoting heterodimerization of two different single chain polypeptides include immunoglobulin CH1 and CL domains, for instance, human CH1 and CL domains.
  • an immunoglobulin heterodimerization domain is a wild-type CH1 domain, such as a wild type IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, or IgM CH1 domain.
  • an immunoglobulin heterodimerization domain is a wild-type human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, or IgM CH1 domain as set forth in SEQ ID NOS:114, 186-192 and 194, respectively, of PCT Publication No. WO2011/090762 (said sequences incorporated by reference herein).
  • an immunoglobulin heterodimerization domain is a wild-type human IgG1 CH1 domain as set forth in SEQ ID NO:114 of WO2011/090762 (said sequence incorporated by reference herein).
  • an immunoglobulin heterodimerization domain is an altered immunoglobulin CH1 domain, such as an altered IgG1, IgG2, IgG3, IgG4, IgA1, IgA2 IgD, IgE, or IgM CH1 domain.
  • an immunoglobulin heterodimerization domain is an altered human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, or IgM CH1 domain.
  • a cysteine residue of a wild-type CH1 domain (e.g., a human CH1) involved in forming a disulfide bond with a wild type immunoglobulin CL domain (e.g., a human CL) is deleted or substituted in the altered immunoglobulin CH1 domain such that a disulfide bond is not formed between the altered CH1 domain and the wild-type CL domain.
  • an immunoglobulin heterodimerization domain is a wild-type CL domain, such as a wild type C ⁇ domain or a wild type C ⁇ domain.
  • an immunoglobulin heterodimerization domain is a wild type human C ⁇ or human C ⁇ domain as set forth in SEQ ID NOS:112 and 113, respectively, of WO2011/090762 (said sequences incorporated by reference herein).
  • an immunoglobulin heterodimerization domain is an altered immunoglobulin CL domain, such as an altered C ⁇ or C ⁇ domain, for instance, an altered human C ⁇ or human C ⁇ domain.
  • a cysteine residue of a wild-type CL domain (e.g., a human CL) involved in forming a disulfide bond with a wild type immunoglobulin CH1 domain (e.g., a human CH1) is deleted or substituted in the altered immunoglobulin CL domain.
  • Such altered CL domains can further comprise an amino acid deletion at their amino-termini.
  • An exemplary C ⁇ domain is set forth in SEQ ID NO:141 of WO2011/090762 (said sequence incorporated by reference herein), in which the first arginine and the last cysteine of the wild type human Ck domain are both deleted.
  • only the last cysteine of the wild type human Ck domain is deleted in the altered Ck domain because the first arginine deleted from the wild type human Ck domain can be provided by a linker that has an arginine at its carboxyl-terminus and links the amino-terminus of the altered Ck domain with another domain (e.g., an immunoglobulin sug-region, such as a sub-region comprising immunoglobulin CH2 and CH3 domains).
  • a linker that has an arginine at its carboxyl-terminus and links the amino-terminus of the altered Ck domain with another domain (e.g., an immunoglobulin sug-region, such as a sub-region comprising immunoglobulin CH2 and CH3 domains).
  • An exemplary C ⁇ domain is set forth in SEQ ID NO:140 of WO2011/090762 (said sequence incorporated by reference herein), in which the first arginine of a wild type human C ⁇ domain is deleted and the cysteine involved in forming a disulfide bond with a cysteine in a CH1 domain is substituted by a serine.
  • an immunoglobulin heterodimerization domain is an altered C ⁇ domain that contains one or more amino acid substitutions, as compared to a wild type C ⁇ domain, at positions that may be involved in forming the interchain-hydrogen bond network at a C ⁇ -C ⁇ interface.
  • an immunoglobulin heterodimerization domain is an altered human C ⁇ domain having one or more amino acids at positions N29, N30, Q52, V55, T56, S68 or T70 that are substituted with a different amino acid. The numbering of the amino acids is based on their positions in the altered human C ⁇ sequence as set forth in SEQ ID NO:141 of WO2011/090762 (said sequence incorporated by reference herein).
  • an immunoglobulin heterodimerization domain is an altered human C ⁇ domain having one, two, three or four amino acid substitutions at positions N29, N30, V55, or T70.
  • the amino acid used as a substitute at the above-noted positions can be an alanine, or an amino acid residue with a bulk side chain moiety such as arginine, tryptophan, tyrosine, glutamate, glutamine, or lysine.
  • Additional amino acid residues that can be used to substitute amino acid residues of the wild type human Ck sequence at the above noted positions include aspartate, methionine, serine and phenyalanine.
  • Exemplary altered human C ⁇ domains are set forth in SEQ ID NOS:142-178 of WO2011/090762 (said sequences incorporated by reference herein).
  • Altered human C ⁇ domains are those that facilitate heterodimerization with a CH1 domain, but minimize homodimerization with another C ⁇ domain.
  • Representative altered human C ⁇ domains are set forth in SEQ ID NOS:160 (N29W V55A T70A), 161 (N29Y V55A T70A), 202 (T70E N29A N30A V55A), 167 (N30R V55A T70A), 168 (N30K V55A T70A), 170 (N30E V55A T70A), 172 (V55R N29A N30A), 175 (N29W N30Y V55A T70E), 176 (N29Y N30Y V55A T70E), 177 (N30E V55A T70E), 178 (N30Y V55A T70E), 838 (N30D V55A T70E), 839 (N30M V55A T70E), 840 (N30S V55A T70E), and 841 (N30F V55A T70E) of WO2011/090762 (said sequences incorporated by reference herein).
  • both the immunoglobulin heterodimerization domains (i.e., immunoglobulin CH1 and CL domains) of a polypeptide heterodimer have mutations so that the resulting immunoglobulin heterodimerization domains form salt bridges (i.e., ionic interactions) between the amino acid residues at the mutated sites.
  • the immunoglobulin heterodimerization domains of a polypeptide heterodimer can be a mutated CH1 domain in combination with a mutated Ck domain.
  • valine at position 68 (V68) of the wild type human CH1 domain is substituted by an amino acid residue having a negative charge (e.g., aspartate or glutamate), whereas leucine at position 29 (L29) of a mutated human Ck domain in which the first arginine and the last cysteine have been deleted is substituted by an amino acid residue having a positive charge (e.g., lysine, arginine or histidine).
  • a negative charge e.g., aspartate or glutamate
  • leucine at position 29 (L29) of a mutated human Ck domain in which the first arginine and the last cysteine have been deleted is substituted by an amino acid residue having a positive charge (e.g., lysine, arginine or histidine).
  • V68 of the wild type CH1 can be substituted by an amino acid residue having a positive charge
  • L29 of a mutated human Ck domain in which the first arginine and the last cysteine have been deleted can be substituted by an amino acid residue having a negative charge
  • Exemplary mutated CH1 sequences in which V68 is substituted by an amino acid with either a negative or positive charge are set forth in SEQ ID NOS:844 and 845 of WO2011/090762 (said sequences incorporated by reference herein).
  • Exemplary mutated Ck sequences in which L29 is substituted by an amino acid with either a negative or positive charge are set forth in SEQ ID NOS:842 and 843 of WO2011/090762 (said sequences incorporated by reference herein).
  • Positions other than V68 of human CH1 domain and L29 of human Ck domain can be substituted with amino acids having opposite charges to produce ionic interactions between the amino acids in addition or alternative to the mutations in V68 of CH1 domain and L29 of Ck domain.
  • Such positions can be identified by any suitable method, including random mutagenesis, analysis of the crystal structure of the CH1-Ck pair to identify amino acid residues at the CH1-Ck interface, and further identifying suitable positions among the amino acid residues at the CH1-Ck interface using a set of criteria (e.g., propensity to engage in ionic interactions, proximity to a potential partner residue, etc.).
  • polypeptide heterodimers of the present disclosure contain only one pair of immunoglobulin heterodimerization domains.
  • a first chain of a polypeptide heterodimer can comprise a CH1 domain as an immunoglobulin heterodimerization domain, while a second chain can comprise a CL domain (e.g., a C ⁇ or C ⁇ ) as an immunoglobulin heterodimerization domain.
  • a first chain can comprise a CL domain (e.g., a C ⁇ or C ⁇ ) as an immunoglobulin heterodimerization domain
  • a second chain can comprise a CH1 domain as an immunoglobulin heterodimerization domain.
  • the immunoglobulin heterodimerization domains of the first and second chains are capable of associating to form a heterodimeric protein of this disclosure.
  • heterodimeric proteins of the present disclosure can have two pairs of immunoglobulin heterodimerization domains.
  • a first chain of a heterodimer can comprise two CH1 domains, while a second chain can have two CL domains that associate with the two CH1 domains in the first chain.
  • a first chain can comprise two CL domains, while a second chain can have two CH1 domains that associate with the two CL domains in the first chain.
  • a first polypeptide chain comprises a CH1 domain and a CL domain
  • a second polypeptide chain comprises a CL domain and a CH1 domain that associate with the CH1 domain and the CL domain, respectively, of the first polypeptide chain.
  • the immunoglobulin heterodimerization domain of each chain can be located amino-terminal to the immunoglobulin constant region of that chain.
  • the immunoglobulin heterodimerization domain in each chain can be located carboxyl-terminal to the immunoglobulin constant region of that chain.
  • both immunoglobulin heterodimerization domains in each chain can be located amino-terminal to the immunoglobulin constant region of that chain.
  • both immunoglobulin heterodimerization domains in each chain can be located carboxyl-terminal to the immunoglobulin constant region of that chain.
  • one immunoglobulin heterodimerization domain in each chain can be located amino-terminal to the immunoglobulin constant region of that chain, while the other immunoglobulin heterodimerization domain of each chain can be located carboxyl-terminal to the immunoglobulin constant region of that chain.
  • the immunoglobulin constant region is interposed between the two immunoglobulin heterodimerization domains of each chain.
  • PSMA-binding polypeptides of the present disclosure comprise an immunoglobulin constant region (also referred to as an constant region) in each polypeptide chain.
  • an immunoglobulin constant region also referred to as an constant region
  • the inclusion of an immunoglobulin constant region slows clearance of the homodimeric and heterodimeric proteins formed from two PSMA-binding polypeptide chains from circulation after administration to a subject.
  • an immunoglobulin constant region further enables relatively easy modulation of dimeric polypeptide effector functions (e.g., ADCC, ADCP, CDC, complement fixation, and binding to Fc receptors), which can either be increased or decreased depending on the disease being treated, as known in the art and described herein.
  • ADCC dimeric polypeptide effector functions
  • ADCP ADCP
  • CDC complement fixation
  • Fc receptors binding to Fc receptors
  • an immunoglobulin constant region of one or both of the polypeptide chains of the polypeptide homodimers and heterodimers of the present disclosure will be capable of mediating one or more of these effector functions
  • one or more of these effector functions are reduced or absent in an immunoglobulin constant region of one or both of the polypeptide chains of the polypeptide homodimers and heterodimers of the present disclosure, as compared to a corresponding wild-type immunoglobulin constant region.
  • an immunoglobulin constant region preferably has reduced or no effector function relative to a corresponding wild-type immunoglobulin constant region.
  • An immunoglobulin constant region present in PSMA binding polypeptides of the present disclosure can comprise of or is derived from part or all of: a CH2 domain, a CH3 domain, a CH4 domain, or any combination thereof.
  • an immunoglobulin constant region can comprise a CH2 domain, a CH3 domain, both CH2 and CH3 domains, both CH3 and CH4 domains, two CH3 domains, a CH4 domain, two CH4 domains, and a CH2 domain and part of a CH3 domain.
  • a CH2 domain that can form an immunoglobulin constant region of a PSMA-binding polypeptide of the present disclosure can be a wild type immunoglobulin CH2 domain or an altered immunoglobulin CH2 domain thereof from certain immunoglobulin classes or subclasses (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgD) and from various species (including human, mouse, rat, and other mammals).
  • immunoglobulin classes or subclasses e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgD
  • a CH2 domain is a wild type human immunoglobulin CH2 domain, such as wild type CH2 domains of human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, or IgD, as set forth in SEQ ID NOS:115, 199-201 and 195-197, respectively, of PCT Publication WO2011/090762 (said sequences incorporated by reference herein).
  • the CH2 domain is a wild type human IgG1 CH2 domain as set forth in SEQ ID NO:115 of WO2011/090762 (said sequence incorporated by reference herein).
  • a CH2 domain is an altered immunoglobulin CH2 region (e.g., an altered human IgG1 CH2 domain) that comprises an amino acid substitution at the asparagine of position 297 (e.g., asparagine to alanine).
  • an amino acid substitution reduces or eliminates glycosylation at this site and abrogates efficient Fc binding to Fc ⁇ R and C1q.
  • the sequence of an altered human IgG1 CH2 domain with an Asn to Ala substitution at position 297 is set forth in SEQ ID NO:324 of WO2011/090762 said (sequence incorporated by reference herein).
  • a CH2 domain is an altered immunoglobulin CH2 region (e.g., an altered human IgG1 CH2 domain) that comprises at least one substitution or deletion at positions 234 to 238.
  • an immunoglobulin CH2 region can comprise a substitution at position 234, 235, 236, 237 or 238, positions 234 and 235, positions 234 and 236, positions 234 and 237, positions 234 and 238, positions 234-236, positions 234, 235 and 237, positions 234, 236 and 238, positions 234, 235, 237, and 238, positions 236-238, or any other combination of two, three, four, or five amino acids at positions 234-238.
  • an altered CH2 region can comprise one or more (e.g., two, three, four or five) amino acid deletions at positions 234-238, for instance, at one of position 236 or position 237 while the other position is substituted.
  • the above-noted mutation(s) decrease or eliminate the antibody-dependent cell-mediated cytotoxicity (ADCC) activity or Fc receptor-binding capability of a polypeptide heterodimer that comprises the altered CH2 domain.
  • the amino acid residues at one or more of positions 234-238 has been replaced with one or more alanine residues.
  • only one of the amino acid residues at positions 234-238 have been deleted while one or more of the remaining amino acids at positions 234-238 can be substituted with another amino acid (e.g., alanine or serine).
  • a CH2 domain is an altered immunoglobulin CH2 region (e.g., an altered human IgG1 CH2 domain) that comprises one or more amino acid substitutions at positions 253, 310, 318, 320, 322, and 331.
  • an immunoglobulin CH2 region can comprise a substitution at position 253, 310, 318, 320, 322, or 331, positions 318 and 320, positions 318 and 322, positions 318, 320 and 322, or any other combination of two, three, four, five or six amino acids at positions 253, 310, 318, 320, 322, and 331.
  • the above-noted mutation(s) decrease or eliminate the complement-dependent cytotoxicity (CDC) of a polypeptide heterodimer that comprises the altered CH2 domain.
  • CDC complement-dependent cytotoxicity
  • an altered CH2 region in addition to the amino acid substitution at position 297, can further comprise one or more (e.g., two, three, four, or five) additional substitutions at positions 234-238.
  • an immunoglobulin CH2 region can comprise a substitution at positions 234 and 297, positions 234, 235, and 297, positions 234, 236 and 297, positions 234-236 and 297, positions 234, 235, 237 and 297, positions 234, 236, 238 and 297, positions 234, 235, 237, 238 and 297, positions 236-238 and 297, or any combination of two, three, four, or five amino acids at positions 234-238 in addition to position 297.
  • an altered CH2 region can comprise one or more (e.g., two, three, four or five) amino acid deletions at positions 234-238, such as at position 236 or position 237.
  • the additional mutation(s) decreases or eliminates the antibody-dependent cell-mediated cytotoxicity (ADCC) activity or Fc receptor-binding capability of a polypeptide heterodimer that comprises the altered CH2 domain.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • the amino acid residues at one or more of positions 234-238 have been replaced with one or more alanine residues.
  • only one of the amino acid residues at positions 234-238 has been deleted while one or more of the remaining amino acids at positions 234-238 can be substituted with another amino acid (e.g., alanine or serine).
  • a mutated CH2 region in addition to one or more (e.g., 2, 3, 4, or 5) amino acid substitutions at positions 234-238, a mutated CH2 region (e.g., an altered human IgG1 CH2 domain) in a fusion protein of the present disclosure can contain one or more (e.g., 2, 3, 4, 5, or 6) additional amino acid substitutions (e.g., substituted with alanine) at one or more positions involved in complement fixation (e.g., at positions I253, H310, E318, K320, K322, or P331).
  • additional amino acid substitutions e.g., substituted with alanine
  • mutated immunoglobulin CH2 regions include human IgG1, IgG2, IgG4 and mouse IgG2a CH2 regions with alanine substitutions at positions 234, 235, 237 (if present), 318, 320 and 322.
  • An exemplary mutated immunoglobulin CH2 region is mouse IGHG2c CH2 region with alanine substitutions at L234, L235, G237, E318, K320, and K322.
  • an altered CH2 region in addition to the amino acid substitution at position 297 and the additional deletion(s) or substitution(s) at positions 234-238, an altered CH2 region (e.g., an altered human IgG1 CH2 domain) can further comprise one or more (e.g., two, three, four, five, or six) additional substitutions at positions 253, 310, 318, 320, 322, and 331.
  • an immunoglobulin CH2 region can comprise a (1) substitution at position 297, (2) one or more substitutions or deletions or a combination thereof at positions 234-238, and one or more (e.g., 2, 3, 4, 5, or 6) amino acid substitutions at positions I253, H310, E318, K320, K322, and P331, such as one, two, three substitutions at positions E318, K320 and K322.
  • the amino acids at the above-noted positions can be substituted by alanine or serine.
  • an immunoglobulin CH2 region polypeptide comprises: (i) an amino acid substitution at the asparagines of position 297 and one amino acid substitution at position 234, 235, 236 or 237; (ii) an amino acid substitution at the asparagine of position 297 and amino acid substitutions at two of positions 234-237; (iii) an amino acid substitution at the asparagine of position 297 and amino acid substitutions at three of positions 234-237; (iv) an amino acid substitution at the asparagine of position 297, amino acid substitutions at positions 234, 235 and 237, and an amino acid deletion at position 236; (v) amino acid substitutions at three of positions 234-237 and amino acid substitutions at positions 318, 320 and 322; or (vi) amino acid substitutions at three of positions 234-237, an amino acid deletion at position 236, and amino acid substitutions at positions 318, 320 and 322.
  • Exemplary altered immunoglobulin CH2 regions with amino acid substitutions at the asparagine of position 297 include: human IgG1 CH2 region with alanine substitutions at L234, L235, G237 and N297 and a deletion at G236 (SEQ ID NO:325 of WO2011/090762, said sequence incorporated by reference herein), human IgG2 CH2 region with alanine substitutions at V234, G236, and N297 (SEQ ID NO:326 of WO2011/090762, said sequence incorporated by reference herein), human IgG4 CH2 region with alanine substitutions at F234, L235, G237 and N297 and a deletion of G236 (SEQ ID NO:322 of WO2011/090762, said sequence incorporated by reference herein), human IgG4 CH2 region with alanine substitutions at F234 and N297 (SEQ ID NO:343 of WO2011/090762, said sequence incorporated by reference herein),
  • an altered CH2 region e.g., an altered human IgG1 CH2 domain
  • an altered CH2 region can contain one or more additional amino acid substitutions at one or more positions other than the above-noted positions.
  • Such amino acid substitutions can be conservative or non-conservative amino acid substitutions.
  • P233 can be changed to E233 in an altered IgG2 CH2 region (see, e.g., SEQ ID NO:326 of WO2011/090762, said sequence incorporated by reference herein).
  • the altered CH2 region can contain one or more amino acid insertions, deletions, or both.
  • the insertion(s), deletion(s) or substitution(s) can be anywhere in an immunoglobulin CH2 region, such as at the N- or C-terminus of a wild type immunoglobulin CH2 region resulting from linking the CH2 region with another region (e.g., a binding domain or an immunoglobulin heterodimerization domain) via a hinge.
  • an altered CH2 region in a polypeptide of the present disclosure comprises or is a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to a wild type immunoglobulin CH2 region, such as the CH2 region of wild type human IgG1, IgG2, or IgG4, or mouse IgG2a (e.g., IGHG2c).
  • a wild type immunoglobulin CH2 region such as the CH2 region of wild type human IgG1, IgG2, or IgG4, or mouse IgG2a (e.g., IGHG2c).
  • An altered immunoglobulin CH2 region in a PSMA-binding polypeptide of the present disclosure can be derived from a CH2 region of various immunoglobulin isotypes, such as IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, and IgD, from various species (including human, mouse, rat, and other mammals).
  • an altered immunoglobulin CH2 region in a fusion protein of the present disclosure can be derived from a CH2 region of human IgG1, IgG2 or IgG4, or mouse IgG2a (e.g., IGHG2c), whose sequences are set forth in SEQ ID NOS:115, 199, 201 and 320 of WO2011/090762 (said sequences incorporated by reference herein).
  • an altered CH2 domain is a human IgG1 CH2 domain with alanine substitutions at positions 235, 318, 320, and 322 (i.e., a human IgG1 CH2 domain with L235A, E318A, K320A and K322A substitutions) (SEQ ID NO:595 of WO2011/090762, said sequence incorporated by reference herein), and optionally an N297 mutation (e.g., to alanine).
  • an altered CH2 domain is a human IgG1 CH2 domain with alanine substitutions at positions 234, 235, 237, 318, 320 and 322 (i.e., a human IgG1 CH2 domain with L234A, L235A, G237A, E318A, K320A and K322A substitutions) (SEQ ID NO:596 of WO2011/090762, said sequence incorporated by reference herein), and optionally an N297 mutation (e.g., to alanine).
  • an altered CH2 domain is an altered human IgG1 CH2 domain with mutations known in the art that enhance immunological activities such as ADCC, ADCP, CDC, complement fixation, Fc receptor binding, or any combination thereof.
  • the CH3 domain that can form an immunoglobulin constant region of a PSMA-binding polypeptide of the present disclosure can be a wild type immunoglobulin CH3 domain or an altered immunoglobulin CH3 domain thereof from certain immunoglobulin classes or subclasses (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, IgM) of various species (including human, mouse, rat, and other mammals).
  • immunoglobulin classes or subclasses e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, IgM
  • a CH3 domain is a wild type human immunoglobulin CH3 domain, such as wild type CH3 domains of human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, or IgM as set forth in SEQ ID NOS:116, 208-210, 204-207, and 212, respectively of WO2011/090762 (said sequences incorporated by reference herein).
  • the CH3 domain is a wild type human IgG1 CH3 domain as set forth in SEQ ID NO:116 of WO2011/090762 (said sequence incorporated by reference herein).
  • a CH3 domain is an altered human immunoglobulin CH3 domain, such as an altered CH3 domain based on or derived from a wild-type CH3 domain of human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, or IgM antibodies.
  • an altered CH3 domain can be a human IgG1 CH3 domain with one or two mutations at positions H433 and N434 (positions are numbered according to EU numbering). The mutations in such positions can be involved in complement fixation.
  • an altered CH3 domain can be a human IgG1 CH3 domain but with one or two amino acid substitutions at position F405 or Y407.
  • an altered CH3 domain can be an altered human IgG1 CH3 domain with its last lysine deleted.
  • sequence of this altered CH3 domain is set forth in SEQ ID NO:761 of WO2011/090762 (said sequence incorporated by reference herein).
  • PSMA-binding polypeptides forming a polypeptide heterodimer comprise a CH3 pair that comprises so called “knobs-into-holes” mutations (see, Marvin and Zhu, Acta Pharmacologica Sinica 26:649-58, 2005; Ridgway et al., Protein Engineering 9:617-21, 1966). More specifically, mutations can be introduced into each of the two CH3 domains of each polypeptide chain so that the steric complementarity required for CH3/CH3 association obligates these two CH3 domains to pair with each other.
  • a CH3 domain in one single chain polypeptide of a polypeptide heterodimer can contain a T366W mutation (a “knob” mutation, which substitutes a small amino acid with a larger one), and a CH3 domain in the other single chain polypeptide of the polypeptide heterodimer can contain a Y407A mutation (a “hole” mutation, which substitutes a large amino acid with a smaller one).
  • Other exemplary knobs-into-holes mutations include (1) a T366Y mutation in one CH3 domain and a Y407T in the other CH3 domain, and (2) a T366W mutation in one CH3 domain and T366S, L368A and Y407V mutations in the other CH3 domain.
  • the CH4 domain that can form an immunoglobulin constant region of PSMA-binding polypeptides of the present disclosure can be a wild type immunoglobulin CH4 domain or an altered immunoglobulin CH4 domain thereof from IgE or IgM molecules.
  • the CH4 domain is a wild type human immunoglobulin CH4 domain, such as wild type CH4 domains of human IgE and IgM molecules as set forth in SEQ ID NOS:213 and 214, respectively, of WO2011/090762 (said sequences incorporated by reference herein).
  • a CH4 domain is an altered human immunoglobulin CH4 domain, such as an altered CH4 domain based on or derived from a CH4 domain of human IgE or IgM molecules, which have mutations that increase or decrease an immunological activity known to be associated with an IgE or IgM Fc region.
  • an immunoglobulin constant region of PSMA binding polypeptides of the present disclosure comprises a combination of CH2, CH3 or CH4 domains (i.e., more than one constant region domain selected from CH2, CH3 and CH4).
  • the immunoglobulin constant region can comprise CH2 and CH3 domains or CH3 and CH4 domains.
  • the immunoglobulin constant region can comprise two CH3 domains and no CH2 or CH4 domains (i.e., only two or more CH3).
  • the multiple constant region domains that form an immunoglobulin constant region can be based on or derived from the same immunoglobulin molecule, or the same class or subclass immunoglobulin molecules.
  • the immunoglobulin constant region is an IgG CH2CH3 (e.g., IgG1 CH2CH3, IgG2 CH2CH3, and IgG4 CH2CH3) and can be a human (e.g., human IgG1, IgG2, and IgG4) CH2CH3.
  • the immunoglobulin constant region comprises (1) wild type human IgG1 CH2 and CH3 domains, (2) human IgG1 CH2 with N297A substitution CH2(N297A)) and wild type human IgG1 CH3, or (3) human IgG1 CH2(N297A) and an altered human IgG1 CH3 with the last lysine deleted.
  • the multiple constant region domains can be based on or derived from different immunoglobulin molecules, or different classes or subclasses immunoglobulin molecules.
  • an immunoglobulin constant region comprises both human IgM CH3 domain and human IgG1 CH3 domain.
  • the multiple constant region domains that form an immunoglobulin constant region can be directly linked together or can be linked to each other via one or more (e.g., about 2-10) amino acids.
  • immunoglobulin constant regions are set forth in SEQ ID NOS:305-309, 321, 323, 341, 342, and 762 of WO2011/090762 (said sequences incorporated by reference herein).
  • the immunoglobulin constant regions of both PSMA-binding polypeptides of a polypeptide homodimer or heterodimer are identical to each other.
  • the immunoglobulin constant region of one polypeptide chain of a heterodimeric protein is different from the immunoglobulin constant region of the other polypeptide chain of the heterodimer.
  • one immunoglobulin constant region of a heterodimeric protein can contain a CH3 domain with a “knob” mutation, whereas the other immunoglobulin constant region of the heterodimeric protein can contain a CH3 domain with a “hole” mutation.
  • the invention also includes nucleic acids (e.g., DNA or RNA) encoding a PSMA-binding polypeptide as described herein, or one or more polypeptide chains of a dimeric or heterodimeric PSMA-binding protein as described herein.
  • Nucleic acids of the invention include nucleic acids having a region that is substantially identical to a polynucleotide as listed in Table 3, infra.
  • a nucleic acid in accordance with the present invention has at least 80%, typically at least about 90%, and more typically at least about 95% or at least about 98% identity to a polypeptide-encoding polynucleotide as listed in Table 3.
  • Nucleic acids of the invention also include complementary nucleic acids.
  • sequences will be fully complementary (no mismatches) when aligned. In other instances, there can be up to about a 20% mismatch in the sequences.
  • nucleic acids encoding both first and second polypeptide chains of a heterodimeric PSMA-binding protein of the invention.
  • the nucleic acid sequences provided herein can be exploited using codon optimization, degenerate sequence, silent mutations, and other DNA techniques to optimize expression in a particular host, and the present invention encompasses such sequence modifications.
  • Polynucleotide molecules comprising a desired polynucleotide sequence are propagated by placing the molecule in a vector.
  • Viral and non-viral vectors are used, including plasmids.
  • the choice of plasmid will depend on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence.
  • Other vectors are suitable for expression in cells in culture.
  • Still other vectors are suitable for transfer and expression in cells in a whole animal or person. The choice of appropriate vector is well within the skill of the art. Many such vectors are available commercially.
  • the partial or full-length polynucleotide is inserted into a vector typically by means of DNA ligase attachment to a cleaved restriction enzyme site in the vector.
  • the desired nucleotide sequence can be inserted by homologous recombination in vivo. Typically this is accomplished by attaching regions of homology to the vector on the flanks of the desired nucleotide sequence. Regions of homology are added by ligation of oligonucleotides, or by polymerase chain reaction using primers comprising both the region of homology and a portion of the desired nucleotide sequence, for example.
  • an expression cassette or system may be employed.
  • a nucleic acid molecule encoding the polypeptide operably linked to regulatory sequences that control transcriptional expression in an expression vector, is introduced into a host cell.
  • expression vectors can include translational regulatory sequences and a marker gene which is suitable for selection of cells that carry the expression vector.
  • the gene product encoded by a polynucleotide of the invention is expressed in any convenient expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems.
  • the polypeptide-encoding polynucleotide is linked to a regulatory sequence as appropriate to obtain the desired expression properties.
  • a regulatory sequence as appropriate to obtain the desired expression properties.
  • These can include promoters, enhancers, terminators, operators, repressors, and inducers.
  • the promoters can be regulated (e.g., the promoter from the steroid inducible pIND vector (Invitrogen)) or constitutive (e.g., promoters from CMV, SV40, Elongation Factor, or LTR sequences). These are linked to the desired nucleotide sequence using the techniques described above for linkage to vectors. Any techniques known in the art can be used.
  • the expression vector will generally provide a transcriptional and translational initiation region, which can be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region.
  • An expression cassette (“expression unit”) can be introduced into a variety of vectors, e.g., plasmid, BAC, YAC, bacteriophage such as lambda, P1, M13, etc., plant or animal viral vectors (e.g., retroviral-based vectors, adenovirus vectors), and the like, where the vectors are normally characterized by the ability to provide selection of cells comprising the expression vectors.
  • the vectors can provide for extrachromosomal maintenance, particularly as plasmids or viruses, or for integration into the host chromosome. Where extrachromosomal maintenance is desired, an origin sequence is provided for the replication of the plasmid, which can be low- or high copy-number.
  • markers are available for selection, particularly those which protect against toxins, more particularly against antibiotics.
  • the particular marker that is chosen is selected in accordance with the nature of the host, where in some cases, complementation can be employed with auxotrophic hosts.
  • Introduction of the DNA construct can use any convenient method, including, e.g., conjugation, bacterial transformation, calcium-precipitated DNA, electroporation, fusion, transfection, infection with viral vectors, biolistics, and the like.
  • proteins for use within the present invention can be produced in genetically engineered host cells according to conventional techniques.
  • Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells (including cultured cells of multicellular organisms), particularly cultured mammalian cells.
  • Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook and Russell, Molecular Cloning: A Laboratory Manual (3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001), and Ausubel et al., Short Protocols in Molecular Biology (4th ed., John Wiley & Sons, 1999).
  • an expression vector will generally include a nucleic acid segment encoding the PSMA-binding polypeptide, operably linked to a promoter.
  • the first and second polypeptide chains can be co-expressed from separate vectors in the host cell for expression of the entire heterodimeric protein.
  • the first and second polypeptide chains are co-expressed from separate expression units in the same vector in the host cell for expression of the entire heterodimeric protein.
  • the expression vector(s) are transferred to a host cell by conventional techniques, and the transfected cells are then cultured by conventional techniques to produce the encoded polypeptide(s) to produce the corresponding PSMA-binding protein.
  • a secretory signal sequence (also known as a leader sequence) is provided in the expression vector.
  • the secretory signal sequence can be that of the native form of the recombinant protein, or can be derived from another secreted protein or synthesized de novo.
  • the secretory signal sequence is operably linked to the polypeptide-encoding DNA sequence, i.e., the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell.
  • Secretory signal sequences are commonly positioned 5′ to the DNA sequence encoding the polypeptide of interest, although certain signal sequences can be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Pat. No. 5,037,743; Holland et al., U.S. Pat. No. 5,143,830).
  • a secretory signal sequence for use in accordance with the present invention has the amino acid sequence MEAPAQLLFLLLLWLPDTTG (SEQ ID NO:85).
  • Cultured mammalian cells are suitable hosts for production of recombinant proteins for use within the present invention.
  • Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981: Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J.
  • suitable mammalian host cells include African green monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21, BHK-570; ATCC CRL 8544, ATCC CRL 10314), canine kidney cells (MDC K; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC CCL61; CHO DG44; CHO DXB11 (Hyclone, Logan, Utah); see also, e.g., Chasin et al., Som. Cell. Molec. Genet.
  • GH1 rat pituitary cells
  • H-4-II-E rat hepatoma cells
  • COS-1 SV40-transformed monkey kidney cells
  • NIH-3T3 murine embryonic cells
  • Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Manassas, Va. Strong transcription promoters can be used, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Pat. No. 4,956,288.
  • Other suitable promoters include those from metallothionein genes (U.S. Pat. Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter.
  • Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as “transfectants.” Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as “stable transfectants.” Exemplary selectable markers include a gene encoding resistance to the antibiotic neomycin, which allows selection to be carried out in the presence of a neomycin-type drug, such as G-418 or the like; the gpt gene for xanthine-guanine phosphoribosyl transferase, which permits host cell growth in the presence of mycophenolic acid/xanthine; and markers that provide resistance to zeocin, bleomycin, blastocidin, and hygromycin (see, e.g., Gatignol et al., Mol.
  • Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as “amplification.” Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes.
  • An exemplary amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate.
  • Other drug resistance genes e.g., hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
  • drug resistance genes e.g., hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
  • eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells.
  • Agrobacterium rhizogenes as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci . ( Bangalore ) 11:47-58, 1987. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Pat. No. 5,162,222 and WIPO publication WO 94/06463.
  • Insect cells can be infected with recombinant baculovirus, commonly derived from Autographa californica nuclear polyhedrosis virus (AcNPV). See King and Possee, The Baculovirus Expression System: A Laboratory Guide (Chapman & Hall, London); O'Reilly et al., Baculovirus Expression Vectors: A Laboratory Manual (Oxford University Press., New York 1994); and Baculovirus Expression Protocols. Methods in Molecular Biology (Richardson ed., Humana Press, Totowa, N.J., 1995). Recombinant baculovirus can also be produced through the use of a transposon-based system described by Luckow et al. ( J. Virol.
  • This system which utilizes transfer vectors, is commercially available in kit form (BAC-TO-BAC kit; Life Technologies, Gaithersburg, Md.).
  • the transfer vector e.g., PFASTBAC1; Life Technologies
  • the transfer vector contains a Tn7 transposon to move the DNA encoding the protein of interest into a baculovirus genome maintained in E. coli as a large plasmid called a “bacmid.” See Hill-Perkins and Possee, J. Gen. Virol. 71:971-976, 1990; Bonning et al., J. Gen. Virol. 75:1551-1556, 1994; and Chazenbalk and Rapoport, J. Biol. Chem.
  • transfer vectors can include an in-frame fusion with DNA encoding a polypeptide extension or affinity tag as disclosed above.
  • a transfer vector containing a protein-encoding DNA sequence is transformed into E. coli host cells, and the cells are screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus.
  • the bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect Spodoptera frugiperda cells, such as Sf9 cells.
  • Recombinant virus that expresses the protein or interest is subsequently produced.
  • Recombinant viral stocks are made by methods commonly used in the art.
  • the recombinant virus is used to infect host cells, typically a cell line derived from the fall armyworm, Spodoptera frugiperda (e.g., Sf9 or Sf21 cells) or Trichoplusia ni (e.g., HIGH FIVE cells; Invitrogen, Carlsbad, Calif.). See generally Glick and Pasternak, Molecular Biotechnology, Principles & Applications of Recombinant DNA (ASM Press, Washington, D.C., 1994). See also U.S. Pat. No. 5,300,435. Serum-free media are used to grow and maintain the cells. Suitable media formulations are known in the art and can be obtained from commercial suppliers.
  • the cells are grown up from an inoculation density of approximately 2-5 ⁇ 10 5 cells to a density of 1-2 ⁇ 10 6 cells, at which time a recombinant viral stock is added at a multiplicity of infection (MOI) of 0.1 to 10, more typically near 3.
  • MOI multiplicity of infection
  • Fungal cells including yeast cells, can also be used within the present invention.
  • Yeast species of in this regard include, e.g., Saccharomyces cerevisiae, Pichia pastoris , and Pichia methanolica .
  • Methods for transforming S. cerevisiae cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Pat. No. 4,599,311; Kawasaki et al., U.S. Pat. No. 4,931,373; Brake, U.S. Pat. No. 4,870,008; Welch et al., U.S. Pat. No.
  • Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine).
  • An exemplary vector system for use in Saccharomyces cerevisiae is the POT1 vector system disclosed by Kawasaki et al. (U.S. Pat. No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media.
  • Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Pat. No.
  • Prokaryotic host cells including strains of the bacteria Escherichia coli, Bacillus , and other genera are also useful host cells within the present invention. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well-known in the art (see, e.g., Sambrook and Russell, supra).
  • the protein When expressing a recombinant protein in bacteria such as E. coli , the protein can be retained in the cytoplasm, typically as insoluble granules, or can be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea.
  • the denatured protein can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution.
  • the protein can be recovered from the cytoplasm in soluble form and isolated without the use of denaturants.
  • the protein is recovered from the cell as an aqueous extract in, for example, phosphate buffered saline.
  • the extract is applied directly to a chromatographic medium, such as an immobilized antibody or heparin-Sepharose column.
  • Secreted proteins can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.
  • Antibodies including single-chain antibodies, can be produced in bacterial host cells according to known methods. See, e.g., Bird et al., Science 242:423-426, 1988; Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988; and Pantoliano et al., Biochem. 30:10117-10125, 1991.
  • Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells.
  • suitable media including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media can also contain such components as growth factors or serum, as required.
  • the growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell.
  • PSMA-binding proteins are purified by conventional protein purification methods, typically by a combination of chromatographic techniques. See generally Affinity Chromatography: Principles & Methods (Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988); Scopes, Protein Purification: Principles and Practice (Springer-Verlag, New York 1994). Proteins comprising an immunoglobulin Fc region can be purified by affinity chromatography on immobilized protein A or protein G. Additional purification steps, such as gel filtration, can be used to obtain the desired level of purity or to provide for desalting, buffer exchange, and the like.
  • the present invention provides a method for treating a disorder characterized by overexpression of PSMA.
  • methods include administering to a subject in need of such treatment a therapeutically effective amount of a PSMA-binding protein as described herein.
  • the PSMA-binding protein comprises at least one effector function selected from antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), such that the PSMA-binding protein induces ADCC and/or CDC against PSMA-expressing cells in the subject.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • the PSMA-binding protein comprises a second binding domain that specifically binds a T cell (e.g., to a TCR complex or component thereof, such as CD3 ⁇ )
  • the PSMA-binding protein induces redirected T-cell cytotoxicity (RTCC) against PSMA-expressing cells in the subject.
  • RTCC T-cell cytotoxicity
  • the disorder is a cancer.
  • Exemplary cancers amenable to treatment in accordance with the present invention include, for example, prostate cancer (e.g., castrate-resistant prostate cancer), colorectal cancer, gastric cancer, clear cell renal carcinoma, bladder cancer, and lung cancer.
  • the disorder is a prostate disorder such as, for example, prostate cancer or benign prostatic hyperplasia (BPH).
  • BPH benign prostatic hyperplasia
  • the disorder is an neovascular disorder such as, for example, a cancer characterized by solid tumor growth.
  • Exemplary cancers with tumor vasculatures characterized by PSMA overexpression and amenable to treatment in accordance with the present invention include, for example, clear cell renal carcinoma (CCRCC), colorectal cancer, breast cancer, bladder cancer, lung cancer, and pancreatic cancer (see, e.g., Baccala et al., Urology 70:385.390, 2007 (expression of PSMA in CCRCC); Liu et al., Cancer Res. 57:3629-3634, 1997 (expression of PSMA in various non-prostate cancers, including renal, urothelial, lung, colon, breast, and adenocarcinaoma to the liver); and Milowsky et al., J. Clin. Oncol. 25:540-547, 2007 (expression in, e.g., kidney, colon, bladder, and pancreatic cancers, and demonstration of specific targeting of tumor vasculature in humans using an anti-PSMA mAb).
  • CCRCC clear cell renal carcinoma
  • colorectal cancer breast
  • the PSMA-binding protein is delivered in a manner consistent with conventional methodologies associated with management of the disease or disorder for which treatment is sought.
  • an effective amount of the PSMA-binding protein is administered to a subject in need of such treatment for a time and under conditions sufficient to prevent or treat the disease or disorder.
  • Subjects for administration of PSMA-binding proteins as described herein include patients at high risk for developing a particular disorder characterized by PSMA overexpression as well as patients presenting with an existing such disorder.
  • the subject has been diagnosed as having the disorder for which treatment is sought.
  • subjects can be monitored during the course of treatment for any change in the disorder (e.g., for an increase or decrease in clinical symptoms of the disorder).
  • the subject does not suffer from another disorder requiring treatment that involves targeting PSMA-expressing cells.
  • compositions or medicants are administered to a patient susceptible to, or otherwise at risk of, a particular disorder in an amount sufficient to eliminate or reduce the risk or delay the onset of the disorder.
  • compositions or medicants are administered to a patient suspected of, or already suffering from such a disorder in an amount sufficient to cure, or at least partially arrest, the symptoms of the disorder and its complications. An amount adequate to accomplish this is referred to as a therapeutically effective dose or amount.
  • agents are usually administered in several dosages until a sufficient response (e.g., inhibition of inappropriate angiogenesis activity) has been achieved. Typically, the response is monitored and repeated dosages are given if the desired response starts to fade.
  • accepted screening methods can be employed to determine risk factors associated with specific disorders or to determine the status of an existing disorder identified in a subject. Such methods can include, for example, determining whether an individual has relatives who have been diagnosed with a particular disorder. Screening methods can also include, for example, conventional work-ups to determine familial status for a particular disorder known to have a heritable component. For example, various cancers are also known to have certain inheritable components.
  • Inheritable components of cancers include, for example, mutations in multiple genes that are transforming (e.g., Ras, Raf, EGFR, cMet, and others), the presence or absence of certain HLA and killer inhibitory receptor (KIR) molecules, or mechanisms by which cancer cells are able to modulate immune suppression of cells like NK cells and T cells, either directly or indirectly (see, e.g., Ljunggren and Malmberg, Nature Rev. Immunol. 7:329-339, 2007; Boyton and Altmann, Clin. Exp. Immunol. 149:1-8, 2007).
  • KIR HLA and killer inhibitory receptor
  • nucleotide probes can be routinely employed to identify individuals carrying genetic markers associated with a particular disorder of interest.
  • ELISA immunoassay methods are available and well-known in the art that employ monoclonal antibody probes to detect antigens associated with specific tumors. Screening can be implemented as indicated by known patient symptomology, age factors, related risk factors, etc. These methods allow the clinician to routinely select patients in need of the methods described herein for treatment. In accordance with these methods, targeting pathological, PSMA-expressing cells can be implemented as an independent treatment program or as a follow-up, adjunct, or coordinate treatment regimen to other treatments.
  • the PSMA-binding protein is formulated as a pharmaceutical composition.
  • a pharmaceutical composition comprising a PSMA-binding protein can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic molecule is combined in a mixture with a pharmaceutically acceptable carrier.
  • a composition is said to be a “pharmaceutically acceptable carrier” if its administration can be tolerated by a recipient patient.
  • Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier.
  • Other suitable carriers are well-known to those in the art. (See, e.g., Gennaro (ed.), Remington's Pharmaceutical Sciences (Mack Publishing Company, 19th ed. 1995).) Formulations can further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc.
  • a pharmaceutical composition comprising a PSMA-binding protein is administered to a subject in a therapeutically effective amount.
  • a PSMA-binding protein can be administered to subjects by a variety of administration modes, including, for example, by intramuscular, subcutaneous, intravenous, intra-atrial, intra-articular, parenteral, intranasal, intrapulmonary, transdermal, intrapleural, intrathecal, and oral routes of administration.
  • an antagonist can be administered to a subject in a single bolus delivery, via continuous delivery (e.g., continuous transdermal delivery) over an extended time period, or in a repeated administration protocol (e.g., on an hourly, daily, or weekly basis).
  • a “therapeutically effective amount” of a composition is that amount that produces a statistically significant effect in amelioration of one or more symptoms of the disorder, such as a statistically significant reduction in disease progression or a statistically significant improvement in organ function.
  • the exact dose will be determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art.
  • Effective dosages of the compositions of the present invention vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, whether treatment is prophylactic or therapeutic, as well as the specific activity of the composition itself and its ability to elicit the desired response in the individual.
  • the patient is a human, but in some diseases, the patient can be a nonhuman mammal.
  • dosage regimens are adjusted to provide an optimum therapeutic response, i.e., to optimize safety and efficacy.
  • a therapeutically effective amount is also one in which any undesired collateral effects are outweighed by the beneficial effects of administering a PSMA-binding protein as described herein.
  • a dosage typically ranges from about 0.1 ⁇ g to 100 mg/kg or 1 ⁇ g/kg to about 50 mg/kg, and more usually 10 ⁇ g to 5 mg/kg of the subject's body weight.
  • an effective amount of the agent is between about 1 ⁇ g/kg and about 20 mg/kg, between about 10 ⁇ g/kg and about 10 mg/kg, or between about 0.1 mg/kg and about 5 mg/kg.
  • Dosages within this range can be achieved by single or multiple administrations, including, e.g., multiple administrations per day or daily, weekly, bi-weekly, or monthly administrations.
  • a regimen consists of an initial administration followed by multiple, subsequent administrations at weekly or bi-weekly intervals.
  • Another regimen consists of an initial administration followed by multiple, subsequent administrations at monthly or bi-monthly intervals.
  • administrations can be on an irregular basis as indicated by monitoring clinical symptoms of the disorder.
  • Dosage of the pharmaceutical composition can be varied by the attending clinician to maintain a desired concentration at a target site.
  • local concentration of the agent in the bloodstream at the target tissue can be between about 1-50 nanomoles of the composition per liter, sometimes between about 1.0 nanomole per liter and 10, 15, or 25 nanomoles per liter depending on the subject's status and projected measured response.
  • Higher or lower concentrations can be selected based on the mode of delivery, e.g., trans-epidermal delivery versus delivery to a mucosal surface.
  • Dosage should also be adjusted based on the release rate of the administered formulation, e.g., nasal spray versus powder, sustained release oral or injected particles, transdermal formulations, etc.
  • the release rate of the administered formulation e.g., nasal spray versus powder, sustained release oral or injected particles, transdermal formulations, etc.
  • slow-release particles with a release rate of 5 nanomolar would be administered at about twice the dosage of particles with a release rate of 10 nanomolar.
  • compositions as described herein can also be used in the context of combination therapy.
  • combination therapy is used herein to denote that a subject is administered at least one therapeutically effective dose of a PSMA-binding protein and another therapeutic agent.
  • a PSMA-binding protein of the present invention can be used in combination with chemotherapy or radiation.
  • a PSMA-binding protein as described herein can work in synergy with conventional types of chemotherapy or radiation.
  • the PSMA-binding protein can further reduce tumor burden and allow more efficient killing by a chemotherapeutic.
  • compositions of the present invention can also be used in combination with immunomodulatory compounds including various cytokines and co-stimulatory/inhibitory molecules. These can include, but are not limited to, the use of cytokines that stimulate anti-cancer immune responses (e.g., IL-2, IL-12, or IL-21).
  • cytokines that stimulate anti-cancer immune responses
  • PSMA-binding proteins can be combined with reagents that co-stimulate various cell surface molecules found on immune-based effector cells, such as the activation of CD137 (see Wilcox et al., J. Clin. Invest. 109:651-9, 2002) or inhibition of CTLA4 (see Chambers et al., Ann. Rev. Immunol. 19:565-94, 2001).
  • PSMA-binding proteins could be used with reagents that induce tumor cell apoptosis by interacting with TNF superfamily receptors (e.g., TRAIL-related receptors, DR4, DR5, Fas, or CD37).
  • TNF superfamily receptors e.g., TRAIL-related receptors, DR4, DR5, Fas, or CD37.
  • reagents include ligands of TNF superfamily receptors, including ligand-Ig fusions, and antibodies specific for TNF superfamily receptors (e.g., TRAIL ligand, TRAIL ligand-Ig fusions, anti-TRAIL antibodies, and the like).
  • Non-measurable disease means the disease comprises of lesions ⁇ 20 mm with conventional techniques or ⁇ 10 mm with spiral CT scan, and truly non-measurable lesions (too small to accurately measure).
  • Non-measurable disease includes pleural effusions, ascites, and disease documented by indirect evidence.
  • CR Complete Response
  • PR Partial Response
  • PD Progressive Disease
  • Stable or No Response defined as not qualifying for CR, PR, or Progressive Disease.
  • OS overall survival
  • DFS disease-free survival
  • ORR objective response rate
  • TTP time to progression
  • PFS progression-free survival
  • compositions can be supplied as a kit comprising a container that comprises the pharmaceutical composition as described herein.
  • a pharmaceutical composition can be provided, for example, in the form of an injectable solution for single or multiple doses, or as a sterile powder that will be reconstituted before injection.
  • a kit can include a dry-powder disperser, liquid aerosol generator, or nebulizer for administration of a pharmaceutical composition.
  • Such a kit can further comprise written information on indications and usage of the pharmaceutical composition.
  • Murine variable domains were cloned from hybridoma cells expressing the 107-1A4 monoclonal antibody specific for human PSMA (see Brown et al, 1998, Prostate Cancer and Prostatic Diseases. 1: 208-215).
  • Total RNA was isolated from the hybridoma using RNeasy® Protect Mini kit (QIAGEN Inc., 74124) according to the manufacturer's instructions.
  • SMARTTM RACE cDNA amplification kit (Clontech Laboratories, Inc., 634914) was used to generate 5′RACE-ready cDNA with oligo(dT) primer according to the manufacturer's instructions.
  • V H and V L regions of antibody were PCR-amplified from cDNA by SMARTTM RACE protocol using pools of proprietary degenerate gene specific primers for different murine VK or VH gene families. PCR amplification products were confirmed by gel electrophoresis, and correct sized bands were isolated and cloned into pCR®2.1-TOPO® plasmid vector using the TOPO® TA Cloning kit according to manufacturer's instructions (Invitrogen Corporation). The resulting recombinant vector was transformed into TOP10 E. coli .
  • Sequencing DNA from clones revealed multiple isolates of a heavy chain region with a murine VH1 framework with high homology (92.7%) to the murine germline framework L17134 (Genbank), and a kappa chain region with a murine Vk16 framework with very high homology (98.6%) to the murine germline framework AJ235936 (EMBL).
  • the polynucleotide sequence of PSMA-specific murine VH region (107-1A4) is given in SEQ ID NO:1, and the amino acid sequence is given in SEQ ID NO:2.
  • the polynucleotide sequence of PSMA-specific murine VL region (107-1A4) with the restriction sites is given in SEQ ID NO:3.
  • the polynucleotide sequence of PSMA-specific murine VL region (107-1A4) modified to remove the restriction sites is given in SEQ ID NO:4, and the amino acid sequence is given in SEQ ID NO:5.
  • DNA sequences coding for these murine scFv sequences and cassetted for insertion into appropriate scaffolds were designed.
  • appropriate scaffolds e.g., SMIP, SCORPION, and mono-specific or multispecific heterodimer polypeptides
  • the constructs were then synthesized by Blue Heron (Bothell, Wash.) and standard, restriction-digest-based cloning techniques were used to produce the gene sequences corresponding to TSC084 (SEQ ID NO:44; amino acid sequence SEQ ID NO:46), TSC085 (SEQ ID NO:36; amino acid sequence SEQ ID NO:38), and TSC092 (SEQ ID NO:37; amino acid sequence SEQ ID NO:39).
  • the humanized PSMA-specific (107-1A4) VL region polynucleotide sequence is given in SEQ ID NO:22, and the amino acid sequence is given in SEQ ID NO:23.
  • a humanized PSMA-specific (107-1A4) VH region #1 polynucleotide sequence is given in SEQ ID NO:24, and the amino acid sequence is given in SEQ ID NO:25.
  • a humanized PSMA-specific (107-1A4) VH region #2 polynucleotide sequence is given in SEQ ID NO:26, and the amino acid sequence is given in SEQ ID NO:27.
  • PSMA-specific Interceptor molecules were made using Interceptor scaffolding as generally disclosed in International Appl. Nos. PCT/US2010/62436 and PCT/US2010/62404. Briefly, PSMA-specific polypeptide heterodimers were made by co-expressing two different polypeptides chains, one polypeptide chain comprising an immunoglobulin CH1 heterodimerization domain and the other polypeptide chain comprising an immunoglobulin CL heterodimerization domain. The day before transfection HEK293 cells were suspended at a cell concentration of 0.5 ⁇ 10 6 cells/ml in GIBCO® FreeStyleTM 293 expression medium (Invitrogen).
  • 250 mls of cells were used for a large transfection, and 60 mls of cells were used for a small transfection.
  • 320 ul of 293FectinTM transfectin reagent (Invitrogen) was mixed with 8 mls of media.
  • 250 ug of DNA of each of the single chain polypeptide was mixed with the 8 mls of media and incubated for 5 minutes. After 15 minutes of incubation, the DNA-293fectin mixture was added to the 250 mls of 293 cells and returned to the shaker at 37° C. and shaken at a speed of 120 RPM.
  • a fourth of the DNA, 293fectin, and media were used for the smaller transfection using 60 mls of cells.
  • Protein A of affinity chromatography was used to purify the proteins. 2 ml of packed protein A agarose (Repligen) was added to a Econo-Column® chromatography column, size 2.5 ⁇ 10 cm (Bio-Rad Laboratories), washed extensively with PBS (10 ⁇ column volume), and the supernatants were loaded, washed with PBS again, and eluted with 3 column volumes of Pierce IgG elution buffer. Proteins were then dialyzed extensively against PBS. Proteins were then concentrated using Amicon® Centricon® centrifugal filter devices (Millipore Corp.) to a final volume around 0.5 ml.
  • Bivalent polypeptide heterodimer TSC122 was made by co-expressing single chain polypeptides TSC084 and TSC093.
  • Single chain polypeptide TSC084 comprises from its amino- to carboxyl-terminus: murine 107-1A4 (anti-PSMA) VL-VH scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human CH1.
  • the nucleotide and amino acid sequences for TSC084 are set forth in SEQ ID NOs:44 and 46, respectively.
  • Single chain polypeptide TSC093 comprises from its amino- to carboxyl-terminus: Cris7 (anti-CD3) scFv, human IgG1 SCC-P hinge, human IgG1CH2, human IgG1 CH3, and human C ⁇ (YAE) (i.e., human C ⁇ without the first Arg or last Cys, but with N30Y, V55A, and T70E substitutions).
  • Cris7 anti-CD3 scFv
  • human IgG1 SCC-P hinge human IgG1CH2, human IgG1 CH3, and human C ⁇ (YAE) (i.e., human C ⁇ without the first Arg or last Cys, but with N30Y, V55A, and T70E substitutions).
  • the nucleotide and amino acid sequences for TSC093 are set forth in SEQ ID NOs:45 and 47, respectively.
  • TSC192 comprises from its amino- to carboxyl-terminus: humanized 107-1A4 (anti-PSMA) VL-VH#2 scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human C ⁇ (YAE).
  • the nucleotide and amino acid sequences for TSC192 are set forth in SEQ ID NOs:53 and 58, respectively.
  • TSC125 comprises from its amino- to carboxyl-terminus: Cris7 (anti-CD3) scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human CH1.
  • the nucleotide and amino acid sequences for TSC125 are set forth in SEQ ID NOs:52 and 57, respectively.
  • TSC193 comprises from its amino- to carboxyl-terminus: humanized 107-1A4 (anti-PSMA) VL-VH#1 scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human C ⁇ (YAE).
  • the nucleotide and amino acid sequences for TSC193 are set forth in SEQ ID NOs: 54 and 59, respectively.
  • TSC125 comprises from its amino- to carboxyl-terminus: Cris7 (anti-CD3) scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human CH1.
  • the nucleotide and amino acid sequences for TSC125 are set forth in SEQ ID NOs:52 and 57, respectively.
  • TSC195 comprises from its amino- to carboxyl-terminus: humanized 107-1A4 (anti-PSMA) VL-VH#2 scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human CH1.
  • the nucleotide and amino acid sequences for TSC195 are set forth in SEQ ID NOs:55 and 60, respectively.
  • TSC093 comprises from its amino- to carboxyl-terminus: Cris7 (anti-CD3) scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human C ⁇ (YAE).
  • the nucleotide and amino acid sequences for TSC093 are set forth in SEQ ID NOs: 45 and 47, respectively.
  • TSC205 Bivalent polypeptide heterodimer TSC205 was made by co-expressing polypeptide chains TSC196 and TSC093.
  • TSC196 comprises from its amino- to carboxyl-terminus: humanized 107-1A4 (anti-PSMA) VL-VH#1 scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human CH1.
  • the nucleotide and amino acid sequences for TSC196 are set forth in SEQ ID NOs:56 and 61, respectively.
  • TSC093 comprises from its amino- to carboxyl-terminus: Cris7 (anti-CD3) scFv, human IgG1 SCC-P hinge, human IgG1 CH2, human IgG1 CH3, and human C ⁇ (YAE).
  • the nucleotide and amino acid sequences for TSC093 are set forth in SEQ ID NOs: 45 and 47, respectively.
  • PSMA-specific SCORPION molecules TSC194 (SEQ ID NO:48 (nucleic acid), SEQ ID NO:49 (amino acid); TSC199 (SEQ ID NO:50 (nucleic acid), SEQ ID NO:51 (amino acid)); TSC 212 (SEQ ID NO:73 (nucleic acid), SEQ ID NO:74 (amino acid)); TSC213 (SEQ ID NO:75 (nucleic acid), SEQ ID NO:76 (amino acid)); TSC249 (SEQ ID NO:77 (nucleic acid), SEQ ID NO:78 (amino acid)); TSC250 (SEQ ID NO:79 (nucleic acid), SEQ ID NO:80 (amino acid)); TSC251 (SEQ ID NO:81 (nucleic acid), SEQ ID NO:82 (amino acid)); and TSC252 (SEQ ID NO:83 (nucleic acid), SEQ ID NO:84 (amino acid)
  • Insertion of the N-terminal scFv binding domain was accomplished through digestion of the parental template and scFv insert with either the restriction enzymes HindIII and XhoI or AgeI and XhoI, desired fragments were identified and isolated by agarose gel purification, and ligation. Insertion of the C-terminal scFv binding domain was accomplished through digestion of the parental template and scFv insert with the restriction enzymes EcoRI and NotI, desired fragments were identified and isolated by agarose gel purification, and ligation.
  • Monoclonal antibodies were purified from hybridoma cell culture media by standard procedures.
  • SMIP, Interceptor, and SCORPION molecules disclosed herein were produced by transient transfection of human HEK293 cells, and purified from cell culture supernatants by Protein A affinity chromatography. If aggregates were detected after affinity chromatography, secondary size exclusion chromatography was also performed to ensure homogeneity of the protein.
  • PSMA+ C4-2, Wu et al., 1994 Int. J. Cancer 57:406-12
  • PSMA ⁇ DU-145, Stone et al., 1978, Intl. J. Cancer 21:274-81 prostate cancer cell lines were performed by standard FACS-based staining procedures.
  • 7-Aminoactinomycin D (7-AAD) staining solution 7-Aminoactinomycin D
  • Binding studies ( FIG. 1 ) were used to compare the parent 107-1A4 murine antibody (i.e., TSC045) with the chimeric SMIP molecules (TSC085, TSC092) and the bispecific, chimeric Interceptor molecule TSC122. Both chimeric SMIP molecules showed comparable affinity to PSMA+ cells as the parent murine antibody, although one (TSC085, with a VL-VH scFv orientation) showed a lower level of saturation on the surface of the cell. The bispecific, chimeric Interceptor molecule (TSC122), which had only a single 107-1A4 binding domain, showed a lower binding affinity to the PSMA+ cells. All showed little to no binding to the PSMA ⁇ cell line DU-145.
  • Binding studies of humanized SMIP molecules TSC188 and TSC189 showed comparable affinities to those previously determined (data not shown) for the parent monoclonal antibody, with similarly high levels of saturation and selectivity for PSMA+C4-2 cells over PSMA ⁇ DU-145 cells.
  • Binding studies of humanized SCORPION molecules TSC194 and TSC199 showed comparable affinities to the parental humanized SMIP molecules TSC188 and TSC189 ( FIG. 2B ), with no binding to the PSMA ⁇ DU-145 cell line.
  • CypHerTM5E Mono NHS Ester GE Healthcare, #PA15401
  • CypHer5E is a pH-sensitive red excited dye that fluoresces at low pH, which is typically encountered inside of endosomes and lysosomes; CypHer5E fluorescence can be used as a proxy for cellular internalization as a result.
  • Dye dissolved in fresh DMSO was added to purified protein in PBS/sodium carbonate buffer, pH 8.3 (9:1), at a dye:protein molar ratio of 20:1. After at least 1 hour incubation in the dark at room temperature, labeled protein was separated from unreacted dye by dialysis at 4° C.
  • PBMC Peripheral blood mononuclear cells
  • C4-2 castration-resistant prostate cancer (CRPC) cells were labeled with CellTrackerTM Green cytoplasmic dye (Invitrogen, C7025) following manufacturer's protocol in order to distinguish them from T cells.
  • Labeled C4-2 cells were seeded into poly-D-lysine-coated 96-well plates, as used in Example 3, at 8000 cells per well in standard growth media, one day before addition of T cells and Interceptor molecule.
  • Ten ul of concentrated bispecific Interceptor molecule (TSC122, TSC200, TSC202, or TSC204) was added to 100 ul of media per well, plus 50 ul of T cells (80,000 cells) in standard growth media. Cell cultures were kept in CO 2 incubator at 37° C. overnight.
  • Imaging and quantitation was performed by use of an InCell Analyzer microscope (GE), collecting data from 10 fields per well.
  • the acquisition protocol was set to collect data with suitable filter sets for: a) nuclei detection via Hoechst stain, b) cell type discrimination via CellTrackerTM Green detection, c) live/dead cell status determination via 7-AAD staining, and bright field images.
  • Quantitation was performed by InCell Workstation software, using a decision tree application. Individual cells were detected by presence of nuclear stain by Hoechst. Threshold values of signal in the green channel (CellTrackerTM Green) were used to split cells into C4-2 (positive) and T cell (negative) populations. Threshold values of signal in red channel (7-AAD) were used to split cells into dead (positive) and live (negative) populations.
  • Bispecific Interceptor molecules featuring either the 107-1A4 murine scFv or humanized 107-1A4 scFv as well as an anti-CD3 scFv (Cris7) were tested for the ability to cross-link T-cells to target PSMA+ tumor cells and enable target-dependent cytotoxic T cell responses (so-called ‘redirected T cell cytotoxicity’, or RTCC).
  • RTCC target-dependent cytotoxic T cell responses
  • Potent target-dependent cytotoxic activity over 24 hours was observed with the chimeric TSC122 Interceptor molecule ( FIG. 4 ) with T-cells from two different donors; roughly 60% of target cells were lysed by treatment with as little as 100 pM of TSC122 Interceptor molecule.
  • the cytotoxic activity of humanized SCORPION molecules (TSC194, TSC199, TSC212, TSC213), compared to that of the chimeric Interceptor molecule TSC122, was also examined ( FIG. 6 ).
  • the humanized SCORPION molecules with anti-PSMA scFvs in the VL-VH orientation (TSC194, TSC199) had comparable cytotoxic activity to the bispecific chimeric Interceptor molecule (also with an scFv in the VL-VH orientation, and also including an anti-CD3 scFv (Cris7)).
  • the humanized SCORPION molecules with anti-PSMA scFvs in the VH-VL orientation on the other hand, had lower overall cytotoxicity.
  • TSC122 a chimeric Interceptor molecule
  • TSC202 humanized Interceptor molecule
  • TSC194 a humanized SCORPION molecule
  • TSC199 a humanized SCORPION molecule
  • C4-2 prostate cancer cells were obtained from MD Anderson Cancer Center (Houston, Tex.) and cultured according to the provided protocol.
  • Peripheral blood mononuclear cells PBMC
  • T cells were further isolated using a Pan T-cell Isolation Kit II from Miltenyi Biotec (Bergisch Gladbach, Germany) using the manufacturer's protocol.
  • CFSE carboxyfluorescein diacetate succinimidyl ester
  • cells were labeled with antibodies for flow cytometric analysis. Cells were labeled and washed in their original plates to minimize cell losses during transfers, and all labeling was done in saline buffer with 0.2% bovine serum albumin.
  • saline buffer with 0.2% bovine serum albumin.
  • cells were pre-incubated with 100 ug/ml human IgG at room temperature for 15 min. Subsequently, cells were incubated with a mixture (total volume 50 ul) of the following dye-labeled antibodies: CD5-PE, CD4-APC, CD8-Pacific Blue, CD25-PE-Cy7, as well as 7-Amino Actinomycin D (7AAD hereafter) for 40 min.
  • FIG. 7A and FIG. 7B Analysis of live CD4+ and CD8+ populations from wells with C4-2 cells treated with T-cells revealed a significant increase in both the total number of cells and percent proliferating cells in the presence of C4-2 cells displaying the target PSMA antigen. Proliferation was slightly higher for CD4+ T-cells than CD8+ T-cells, and the proliferation induced by the Interceptor molecules TSC122 and TSC202 saturated at a higher level than the responses induced by the SCORPION molecules TSC194 and TSC199. All molecules showed induction of T-cell proliferation at low concentrations (100 pM). No significant differences in relative induction of CD4+ versus CD8+ cell proliferation were apparent between molecules.
  • anti-PSMA murine monoclonal antibody 107-1A4 chimeric 107-1A4 SMIP molecule (TSC085) and humanized 107-1A4 SMIP molecule (TSC189) binds a unique epitope on PSMA, which is not recognized by common literature antibodies (J415, J591), and that the conversion of murine monoclonal antibody 107-1A4 to SMIP format did not result in a shift in that binding epitope, competition binding experiments were carried out.
  • Hybridomas producing the J591, Hu591 (a humanized version of J591) and J415 antibodies were obtained from ATCC.
  • Monoclonal antibodies were purified from hybridoma cell culture media by standard procedures.
  • SMIP molecules were produced by transient transfection of human 293 cells, and purified from cell culture supernatants by Protein A affinity chromatography. If aggregates were detected after affinity chromatography, secondary size exclusion chromatography was also performed to ensure homogeneity of the protein.
  • FACS buffer PBS+2% normal goat serum+2% fetal bovine serum+0.1% sodium azide
  • FIG. 8A Competitive binding studies were used to see if the humanized J591 antibody, Hu591, could compete with the binding of 107-1A4, J591 or J415 murine antibodies to cells. No competition was observed for the binding of 107-1A4, suggesting it binds a non-competitive epitope; competition was observed for the binding of both J591 and J415 antibodies, however.
  • additional binding studies were carried out to see if the three murine antibodies could compete with the binding of the chimeric 107-1A4 SMIP molecule TSC085 to cells ( FIG. 8B ). Strong competition was seen from binding of the parental 107-1A4 antibody, confirming that the SMIP molecule bound to the same epitope.
  • an anti-PSMA bispecific molecule of the present disclosure e.g., anti-PSMA and anti-CD3 bispecific molecules
  • the anti-PSMA bispecific molecule is evaluated as follows.
  • PSMA-expressing tumor cell lines (such as LNCaP, LNCaP C4-2, LNCaP C4-2B, VCaP, CWR22Rv1, LAPC4, MDA-PCa-2b, LuCaP 23.1, LuCaP 58, LuCaP 70, LuCaP 77) are mixed with human lymphocytes (either human peripheral blood mononuclear cells or purified T-cells) and injected subcutaneously into immunodeficient mice (such as SCID, NOD/SCID, etc).
  • An anti-PSMA bispecific molecule is injected intravenously on the day of injection and on several subsequent days. Dose-dependent inhibition of tumor outgrowth, as assessed by tumor volume, indicates that the respective molecule has efficacy against PSMA-expressing tumors in vivo.
  • PSMA-expressing tumor cell lines (such as LNCaP, LNCaP C4-2, LNCaP C4-2B, VCaP, CWR22Rv1, LAPC4, MDA-PCa-2b, LuCaP 23.1AI, LuCaP 58, LuCaP 70, LuCaP 77) are injected subcutaneously into immunodeficient mice (such as SCID, NOD/SCID, etc). Tumor growth is monitored, and the study is initiated when tumors show signs of established growth (typically a volume of ⁇ 200 mm3). Human lymphocytes (either human peripheral blood mononuclear cells or purified T-cells) are injected intravenously along with an anti-PSMA bispecific molecule on the day of injection. The anti-PSMA bispecific molecule is injected several subsequent days. Dose-dependent inhibition of tumor growth, as assessed by tumor volume, indicates that the respective molecule has efficacy against PSMA-expressing tumors in vivo.
  • immunodeficient mice such as SCID, NOD
  • PSMA-expressing tumor cell lines (such as LNCaP C4-2, LNCaP C4-2B, VCaP, CWR22Rv1, LAPC4, MDA-PCa-2b, LuCaP 23.1, LuCaP 58, LuCaP 70, LuCaP 77) are mixed with human lymphocytes (either human peripheral blood mononuclear cells or purified T-cells) and injected intra-tibially into immunodeficient mire (such as SCID, NOD/SCID, etc).
  • An anti-PSMA bispecific molecule is injected intravenously on the day of injection and on several subsequent days. Dose-dependent inhibition of tumor growth, as assessed by serum biomarkers, radiography, fluorescent imaging, weight loss, and other proxy measurements of tumor volume, indicates that the respective molecule has efficacy against PSMA-expressing tumors in vivo.
  • PSMA-expressing tumor cell lines (such as LNCaP C4-2, LNCaP C4-2B, VCaP, CWR22Rv1, LAPC4, MDA-PCa-2b, LuCaP 23.1AI, LuCaP 58, LuCaP 70, LuCaP 77) are injected intra-tibially into immunodeficient mice (such as SCID, NOD/SCID, etc). Tumor growth is monitored, and the study is initiated when tumors show signs of established growth (typically a volume of ⁇ 200 mm3).
  • Human lymphocytes either human peripheral blood mononuclear cells or purified T-cells
  • an anti-PSMA bispecific molecule on the day of injection.
  • the anti-PSMA bispecific molecule is injected several subsequent days. Dose-dependent inhibition of tumor growth, as assessed by serum biomarkers, radiography, fluorescent imaging, weight loss, and other proxy measurements of tumor volume, indicates that the respective molecule has efficacy against PSMA expressing tumors in vivo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
US14/113,353 2011-04-22 2012-04-20 Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods Abandoned US20140161800A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/113,353 US20140161800A1 (en) 2011-04-22 2012-04-20 Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
US15/585,921 US9782478B1 (en) 2011-04-22 2017-05-03 Prostate-specific membrane antigen binding proteins and related compositions and methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478449P 2011-04-22 2011-04-22
US14/113,353 US20140161800A1 (en) 2011-04-22 2012-04-20 Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
PCT/US2012/034575 WO2012145714A2 (en) 2011-04-22 2012-04-20 Prostate-specific membrane antigen binding proteins and related compositions and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/034575 A-371-Of-International WO2012145714A2 (en) 2011-04-22 2012-04-20 Prostate-specific membrane antigen binding proteins and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/585,921 Continuation US9782478B1 (en) 2011-04-22 2017-05-03 Prostate-specific membrane antigen binding proteins and related compositions and methods

Publications (1)

Publication Number Publication Date
US20140161800A1 true US20140161800A1 (en) 2014-06-12

Family

ID=47042195

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/113,353 Abandoned US20140161800A1 (en) 2011-04-22 2012-04-20 Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
US15/585,921 Expired - Fee Related US9782478B1 (en) 2011-04-22 2017-05-03 Prostate-specific membrane antigen binding proteins and related compositions and methods
US15/699,474 Abandoned US20180100021A1 (en) 2011-04-22 2017-09-08 Prostate-specific membrane antigen binding proteins and related compositions and methods
US16/871,597 Pending US20210095046A1 (en) 2011-04-22 2020-05-11 Prostate-specific membrane antigen binding proteins and related compositions and methods

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/585,921 Expired - Fee Related US9782478B1 (en) 2011-04-22 2017-05-03 Prostate-specific membrane antigen binding proteins and related compositions and methods
US15/699,474 Abandoned US20180100021A1 (en) 2011-04-22 2017-09-08 Prostate-specific membrane antigen binding proteins and related compositions and methods
US16/871,597 Pending US20210095046A1 (en) 2011-04-22 2020-05-11 Prostate-specific membrane antigen binding proteins and related compositions and methods

Country Status (15)

Country Link
US (4) US20140161800A1 (enrdf_load_stackoverflow)
EP (1) EP2699596A4 (enrdf_load_stackoverflow)
JP (3) JP2014518615A (enrdf_load_stackoverflow)
CN (1) CN103687872A (enrdf_load_stackoverflow)
AU (1) AU2012245260B2 (enrdf_load_stackoverflow)
BR (1) BR112013027224A8 (enrdf_load_stackoverflow)
CA (1) CA2833019A1 (enrdf_load_stackoverflow)
IL (1) IL228991A0 (enrdf_load_stackoverflow)
MX (1) MX355908B (enrdf_load_stackoverflow)
MY (1) MY171343A (enrdf_load_stackoverflow)
RU (1) RU2632647C2 (enrdf_load_stackoverflow)
SG (1) SG194510A1 (enrdf_load_stackoverflow)
UA (1) UA118950C2 (enrdf_load_stackoverflow)
WO (1) WO2012145714A2 (enrdf_load_stackoverflow)
ZA (1) ZA201307559B (enrdf_load_stackoverflow)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130819A3 (en) * 2015-02-11 2016-09-29 Aptevo Research And Development Llc. Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US9782478B1 (en) 2011-04-22 2017-10-10 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
CN108350048A (zh) * 2015-08-07 2018-07-31 阿列索治疗公司 具有SIRP-α结构域或其变体的构建体
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20210347848A1 (en) * 2018-08-31 2021-11-11 ALX Oncology Inc. Decoy polypeptides
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
US20220195041A1 (en) * 2019-05-07 2022-06-23 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
WO2023026235A1 (en) * 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
US12378536B1 (en) 2015-05-11 2025-08-05 David Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201608307WA (en) * 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
EP3243837A4 (en) * 2015-01-08 2018-12-05 Kyowa Hakko Kirin Co., Ltd. Bispecific antibody binding to trailr2 and psma
EP3387013B1 (en) * 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EP3607319A1 (en) * 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
AU2019243764B2 (en) * 2018-03-28 2025-07-24 Mitsubishi Tanabe Pharma Corporation Drug conjugates of cMET monoclonal binding agents, and uses thereof
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
JOP20210323A1 (ar) 2019-06-14 2023-01-30 Teneobio Inc ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
CN111303288B (zh) * 2020-03-04 2020-12-25 和铂医药(苏州)有限公司 一种分离的结合抗原psma的蛋白及其用途
AU2021390501A1 (en) * 2020-12-01 2023-06-29 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
US12275798B2 (en) 2021-06-17 2025-04-15 Boehringer Ingelheim International Gmbh Tri-specific binding molecules
CN113402590B (zh) * 2021-07-14 2022-05-10 呈诺再生医学科技(珠海横琴新区)有限公司 Khl多肽及其在制备tabp-eic细胞中的应用
CN119053342A (zh) * 2022-01-21 2024-11-29 礼进生物医药控股有限公司 用于亲合力受体交联和免疫调节的多特异性抗体
AU2023223455A1 (en) 2022-02-23 2024-08-29 Janssen Biotech, Inc. Anti-cd28 x anti-psma antibodies
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US20030118592A1 (en) * 2001-01-17 2003-06-26 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20050136049A1 (en) * 2001-01-17 2005-06-23 Ledbetter Jeffrey A. Binding constructs and methods for use thereof
US7875278B2 (en) * 2005-02-18 2011-01-25 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
US20110081345A1 (en) * 2007-04-18 2011-04-07 Moore Margaret D Single chain fc, methods of making and methods of treatment
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
EP0914155B1 (en) 1996-03-25 2006-02-22 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
HK1049015B (en) 1999-07-29 2007-09-21 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7045605B2 (en) 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
ES2606537T3 (es) 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CN1189483C (zh) 2001-11-23 2005-02-16 上海中信国健药业有限公司 人源化抗cd3单克隆抗体
EP1519747A4 (en) 2002-01-28 2006-03-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587837B1 (en) 2003-01-28 2012-06-13 Proscan RX Pharma Inc. Epitope sequences for prostate cancer diagnosis and treatment
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
AU2004268932B2 (en) 2003-06-13 2010-06-24 Immunomedics, Inc. D-amino acid peptides
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
CA2534898A1 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
ES2341252T3 (es) 2003-11-28 2010-06-17 Micromet Ag Composiciones que comprenden polipeptidos.
US20050202020A1 (en) 2004-01-09 2005-09-15 Jeffrey Ross Diagnosing and treating cancer
MXPA06009253A (es) 2004-02-16 2007-04-18 Micromet Ag Moleculas de enlace menos inmunogenicas.
US7910693B2 (en) 2004-04-19 2011-03-22 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
AU2005250370B2 (en) * 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
WO2005123129A2 (en) 2004-06-14 2005-12-29 Regents Of The University Of California Methods of redistributing apical target antigens to detect and treat cellular proliferative disease
JP5014988B2 (ja) 2004-07-16 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト 発現増強ポリペプチド
US8066989B2 (en) 2004-11-30 2011-11-29 Trion Pharma Gmbh Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
CN103555733A (zh) 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
NZ556661A (en) 2005-02-18 2010-10-29 Medarex Inc Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
BRPI0612529A2 (pt) 2005-06-20 2010-11-23 Psma Dev Company Llc conjugados de anticorpo-medicamento de psma
WO2007014278A2 (en) * 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
CN2859269Y (zh) * 2005-11-22 2007-01-17 长沙凯维科技有限公司 一种烟花电点火头
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
PL2177536T3 (pl) 2006-03-30 2014-11-28 Glaxo Group Ltd Przeciwciała przeciwko peptydowi beta-amyloidu
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CN101675077B (zh) 2007-04-03 2013-09-04 安进研发（慕尼黑）股份有限公司 跨种特异性的双特异性结合剂
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US9364557B2 (en) 2007-08-01 2016-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fold-back diabody diphtheria toxin immunotoxin and methods of use
EP2033657A1 (de) 2007-09-04 2009-03-11 Trion Pharma Gmbh Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination
EP2281004A4 (en) 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
JP5380931B2 (ja) * 2008-07-14 2014-01-08 日本ポリウレタン工業株式会社 メチレン架橋ポリフェニルポリイソシアネートの製造方法
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
ME02485B (me) 2008-10-01 2017-02-20 Amgen Res Munich Gmbh Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
KR20190064664A (ko) * 2008-10-02 2019-06-10 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
MX2011003763A (es) * 2008-10-10 2011-04-27 Emergent Product Dev Seattle Inmunoterapeuticos de completo tcr.
FI3903829T3 (fi) 2009-02-13 2023-06-13 Immunomedics Inc Solunsisäisesti katkeavan sidoksen omaavia immunokonjugaatteja
EP2241618A1 (en) * 2009-04-14 2010-10-20 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
US8629247B2 (en) 2009-04-14 2014-01-14 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them
JP2013514788A (ja) 2009-12-23 2013-05-02 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法２
NZ600820A (en) 2009-12-29 2014-12-24 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP4279512A3 (en) 2010-11-30 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
CA2828347A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
MX348071B (es) 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2525222A1 (en) 2011-05-17 2012-11-21 Markus M. Heiss Initial relative lymphocyte count as predictive biomarker
CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
PL2748201T3 (pl) 2011-08-23 2018-04-30 Roche Glycart Ag Aktywujące komórki t dwuswoiste cząsteczki wiążące antygen
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
ES2628075T3 (es) 2011-12-19 2017-08-01 Synimmune Gmbh Molécula de anticuerpo biespecífica
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
ES2653287T3 (es) 2012-01-13 2018-02-06 Julius-Maximilians-Universität Würzburg Complementación funcional bipartita inducida por antígenos duales
WO2013121175A1 (en) 2012-02-16 2013-08-22 Ucl Business Plc Lysosome-cleavable linker
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CA2864177C (en) 2012-03-01 2019-11-26 Amgen Research (Munich) Gmbh Prolonged half-life albumin-binding protein fused bispecific antibodies
WO2013132268A1 (en) 2012-03-09 2013-09-12 Ucl Business Plc Chemical modification of antibodies
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
EP2849789A4 (en) 2012-05-14 2016-02-24 Hoffmann La Roche COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
PT2850106T (pt) 2012-05-18 2022-07-18 Aptevo Res & Development Llc Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3
US20130309234A1 (en) 2012-05-18 2013-11-21 Trion Pharma Gmbh Correlation of de novo-induced tumor-associated humoral immune responses with improved clinical outcome
WO2013181087A2 (en) 2012-06-01 2013-12-05 Ibc Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
WO2014012085A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR20140036905A (ko) 2012-09-18 2014-03-26 삼성전자주식회사 이중특이 항체를 포함하는 단백질 복합체
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
CN104271602B (zh) 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
WO2014100490A1 (en) 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US20030118592A1 (en) * 2001-01-17 2003-06-26 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20050136049A1 (en) * 2001-01-17 2005-06-23 Ledbetter Jeffrey A. Binding constructs and methods for use thereof
US7875278B2 (en) * 2005-02-18 2011-01-25 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
US20110081345A1 (en) * 2007-04-18 2011-04-07 Moore Margaret D Single chain fc, methods of making and methods of treatment
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
Alberola-Ila et al. (J. Immunol. 1991 Feb 15; 146 (4): 1085-92). *
Bühler et al. (Cancer Immunol. Immunother. 2008 Jan; 57 (1): 43-52). *
Bander et al. (J. Urol. 2003 Nov; 170 (5):1717-21) *
Caldas et al. (Mol. Immunol. 2003 May; 39 (15): 941-952) *
Carter (J. Immunol. Methods. 2001 Feb 1; 248 (1-2): 7-15). *
Casset et al. (Biochem. Biophys. Res. Commun. 2003 Jul 18; 307 (1): 198-205). *
Chien et al. (Proc. Natl. Acad. Sci. USA. 1989 Jul; 86 (14): 5532-5536) *
De Pascalis et al. (J. Immunol. 2002; 169 (6): 3076-3084) *
Evazalipour et al. (Hybridoma (Larchmt). 2012 Dec; 31 (6): 424-9) *
Fortmüller et al. (Prostate. 2011 May; 71 (6): 588-96 *
George et al. (Circulation. 1998; 97: 900-906) *
Giusti et al. (Proc. Natl. Acad. Sci. USA. 1987 May; 84 (9): 2926-2930) *
Gussow et al. (Methods in Enzymology. 1991; 203: 99-121) *
Holliger et al. (Nat. Biotechnol. 2005 Sep; 23 (9): 1126-36) *
Holm et al. (Mol. Immunol. 2007 Feb; 44 (6): 1075-1084) *
Hu et al. (Cancer Res. 1996 Jul 1; 56 (13): 3055-61) *
Inoue et al. (Appl. Microbiol. Biotechnol. 1997 Oct; 48 (4): 487-92) *
Kim et al. (Mol. Cancer Ther. 2008 Aug; 7 (8): 2486-97). *
Müller et al. (FEBS Lett. 1998 Jan 30; 422 (2): 259-64). *
MacCallum et al. (J. Mol. Biol. 1996 Oct 11; 262 (5): 732-745) *
Mariuzza et al. (Annu. Rev. Biophys. Biophys. Chem. 1987; 16: 139-159) *
Marvin et al. (Acta Pharmacol. Sin. 2005 Jun; 26 (6): 649-58). *
Muyldermans (J. Biotechnol. 2001 Jun; 74 (4): 277-302) *
Omidfar et al. (Tumour Biol. 2004 Jul-Aug; 25 (4): 179-87) *
Orcutt et al. (Protein Eng. Des. Sel. 2010 Apr; 23 (4): 221–228) *
Rudikoff et al (Proc. Natl. Acad. Sci. USA. 1982; 79: 1979-1983) *
Shen et al. (J. Biol. Chem. 2006 Apr 21; 281 (16): 10706-14) *
Vajdos et al. (J. Mol. Biol. 2002 Jul 5; 320 (2): 415-428) *
Wang et al. (Int. J. Cancer. 2001 Jun 15; 92 (6): 871-6). *
Winkler et al. (J. Immunol. 2000 Oct 15; 165 (8): 4505-4514) *
Wu et al. (J. Mol. Biol. 1999 Nov 19; 294 (1): 151-162) *
Zhang et al. (Cancer Res. 1995 Aug 15; 55 (16): 3584-91). *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782478B1 (en) 2011-04-22 2017-10-10 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US11633435B1 (en) 2014-09-18 2023-04-25 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10729731B1 (en) 2014-09-18 2020-08-04 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11813295B1 (en) 2014-09-18 2023-11-14 Theobald Therapeutics LLC Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10828356B1 (en) 2014-09-18 2020-11-10 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10449237B1 (en) 2014-09-18 2019-10-22 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016130819A3 (en) * 2015-02-11 2016-09-29 Aptevo Research And Development Llc. Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
US12378536B1 (en) 2015-05-11 2025-08-05 David Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11639376B2 (en) 2015-08-07 2023-05-02 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
US11208459B2 (en) 2015-08-07 2021-12-28 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
US10696730B2 (en) 2015-08-07 2020-06-30 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
US10259859B2 (en) * 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
CN108350048A (zh) * 2015-08-07 2018-07-31 阿列索治疗公司 具有SIRP-α结构域或其变体的构建体
AU2021218004B2 (en) * 2015-08-07 2023-06-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20210347848A1 (en) * 2018-08-31 2021-11-11 ALX Oncology Inc. Decoy polypeptides
US20220195041A1 (en) * 2019-05-07 2022-06-23 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
WO2023026235A1 (en) * 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
US11987641B2 (en) 2021-08-27 2024-05-21 Janssen Biotech, Inc. Anti-PSMA antibodies and uses thereof

Also Published As

Publication number Publication date
EP2699596A4 (en) 2015-01-14
NZ616481A (en) 2015-08-28
BR112013027224A8 (pt) 2018-08-14
AU2012245260B2 (en) 2016-09-08
MX355908B (es) 2018-05-04
CN103687872A (zh) 2014-03-26
JP2017127305A (ja) 2017-07-27
RU2013142600A (ru) 2015-05-27
EP2699596A2 (en) 2014-02-26
WO2012145714A2 (en) 2012-10-26
US20170306045A1 (en) 2017-10-26
AU2012245260A1 (en) 2013-10-31
IL228991A0 (en) 2013-12-31
CA2833019A1 (en) 2012-10-26
US20180100021A1 (en) 2018-04-12
US20210095046A1 (en) 2021-04-01
JP6585105B2 (ja) 2019-10-02
US9782478B1 (en) 2017-10-10
SG194510A1 (en) 2013-12-30
RU2632647C2 (ru) 2017-10-06
JP2014518615A (ja) 2014-08-07
UA118950C2 (uk) 2019-04-10
JP2019165734A (ja) 2019-10-03
BR112013027224A2 (pt) 2016-12-27
WO2012145714A3 (en) 2012-12-27
MY171343A (en) 2019-10-09
ZA201307559B (en) 2017-06-28
MX2013012127A (es) 2013-11-21

Similar Documents

Publication Publication Date Title
US9782478B1 (en) Prostate-specific membrane antigen binding proteins and related compositions and methods
US20180022819A1 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
US11939392B2 (en) CD123 binding proteins and related compositions and methods
US10202452B2 (en) CD3 binding polypeptides
US11312786B2 (en) Oncofetal antigen binding proteins and related compositions and methods
EP3352760A2 (en) Cd3 binding polypeptides
WO2016094873A2 (en) Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
WO2014151438A1 (en) Multispecific anti-cd37 antibodies and related compositions and methods
NZ616481B2 (en) Prostate-specific membrane antigen binding proteins and related compositions and methods
KR20250133692A (ko) 이중특이성 pd-l1 및 cd40 결합 분자 그리고 이의 용도
AU2024206470A1 (en) Bispecific pd-l1 and cd40 binding molecules and uses thereof
HK1194077A (en) Prostate-specific membrane antigen binding proteins and related compositions and methods

Legal Events

Date Code Title Description
AS Assignment

Owner name: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC, WASHING

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLANKENSHIP, JOHN W.;SEWELL, ELAINE TODD;TAN, PHILIP;SIGNING DATES FROM 20131212 TO 20131216;REEL/FRAME:032206/0060

AS Assignment

Owner name: APTEVO RESEARCH AND DEVELOPMENT LLC, WASHINGTON

Free format text: CHANGE OF NAME;ASSIGNOR:EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC;REEL/FRAME:039382/0985

Effective date: 20160415

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION